WO2010032128A1 - Pharmaceutical dosage forms comprising poly(e-caprolactone) - Google Patents

Pharmaceutical dosage forms comprising poly(e-caprolactone) Download PDF

Info

Publication number
WO2010032128A1
WO2010032128A1 PCT/IB2009/006917 IB2009006917W WO2010032128A1 WO 2010032128 A1 WO2010032128 A1 WO 2010032128A1 IB 2009006917 W IB2009006917 W IB 2009006917W WO 2010032128 A1 WO2010032128 A1 WO 2010032128A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
extended release
pharmaceutical dosage
solid oral
release pharmaceutical
Prior art date
Application number
PCT/IB2009/006917
Other languages
French (fr)
Inventor
Meridith Lee Machonis
Original Assignee
Purdue Pharma L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ592276A priority Critical patent/NZ592276A/en
Priority to US13/055,535 priority patent/US20110165248A1/en
Application filed by Purdue Pharma L.P. filed Critical Purdue Pharma L.P.
Priority to JP2011527420A priority patent/JP5539991B2/en
Priority to AU2009294308A priority patent/AU2009294308B2/en
Priority to ES09786269.2T priority patent/ES2586439T3/en
Priority to BRPI0913724A priority patent/BRPI0913724B8/en
Priority to UAA201104686A priority patent/UA101405C2/en
Priority to KR1020117008610A priority patent/KR101456741B1/en
Priority to CA2737257A priority patent/CA2737257C/en
Priority to RU2011121010/15A priority patent/RU2523896C2/en
Priority to CN200980136742.4A priority patent/CN102159193B/en
Priority to EP09786269.2A priority patent/EP2344136B1/en
Priority to MX2011002966A priority patent/MX342643B/en
Publication of WO2010032128A1 publication Critical patent/WO2010032128A1/en
Priority to IL211314A priority patent/IL211314A/en
Priority to ZA2011/01948A priority patent/ZA201101948B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to pharmaceutical dosage forms, for example pharmaceutical dosage forms comprising poly( ⁇ -caprolactone), and processes of manufacture, uses, and methods of treatment thereof.
  • Extended release oral dosage forms allow a specific release of active agent over an extended period of time. Larger dosing intervals, e.g. twice- or once-a- day dosing, may provide fewer side effects and overall better patient compliance.
  • compositions and in particular extended release dosage forms which usually comprise a larger amount of active agent in a single dose are increasingly the subject of abuse.
  • a particular dose of opioid agonist may be more potent when administered parenterally as compared to the same dose administered orally.
  • Some formulations can be tampered with to provide the opioid agonist contained therein for illicit use.
  • Controlled release opioid agonist formulations are sometimes milled or ground, and/or subject to extraction with solvents (e.g., ethanol) by drug abusers to provide the opioid contained therein for immediate release upon oral or parenteral administration.
  • Extended release opioid agonist dosage forms which can liberate a portion of the opioid upon exposure to ethanol, can also result in a patient receiving the dose more rapidly than intended if a patient concomitantly uses alcohol with the dosage form.
  • extended release pharmaceutical oral dosage forms There continues to exist a need in the art for extended release pharmaceutical oral dosage forms. In particular there continues to exist a need for such dosage forms that resist illicit use and are safe when concomitantly used with alcohol.
  • the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent.
  • the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent, wherein at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of at least 10,000.
  • the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent, wherein poly( ⁇ -caprolactone) is present at an amount of at least about 50 weight-% of the extended release matrix formulation.
  • the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent, wherein the multi particulates have a diameter in the range of about 0.1 to about 3 mm.
  • the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent, and additionally comprising at least one high molecular weight polyethylene oxide.
  • the invention encompasses a solid extended release pharmaceutical dosage form as described in the above paragraphs, wherein the active agent is an opioid analgesic, in particular selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, and mixtures of any of the foregoing.
  • the active agent is an opioid analgesic, in particular selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, and mixtures of any of the foregoing.
  • the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent, wherein the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C, between 12.5 % and 55 % (by wt) active agent released after 1 hour, between 25 % and 65 % (by wt) active agent released after 2 hours, between 45 % and 85 % (by wt) active agent released after 4 hours and between 55 % and 95 % (by wt) active agent released after 6 hours.
  • These dosage forms comprise in particular oxycodone hydrochloride, hydromorphone hydrochloride, morphine sulfate or oxymorphone hydrochloride in the active agent.
  • the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent, wherein the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C between 10 % and 30% (by wt) active agent released after 2 hour, 40 % and 75 % (by wt) active agent released after 8 hours and no less than 80%(by wt) active agent released after 22 hours.
  • the invention further encompasses a method of treatment wherein a dosage form comprising an opioid analgesic as described herein is administered for treatment of pain to a patient in need thereof.
  • the invention further encompasses the use of a dosage form comprising an opioid analgesic as described herein for the manufacture of a medicament for the treatment of pain.
  • the invention further encompasses the use of poly( ⁇ -caprolactone) as matrix forming material in the manufacture of a solid extended release dosage form comprising an active agent selected from opioids for imparting to the solid extended release dosage form resistance to milling.
  • the invention further encompasses a process of preparing a solid extended release pharmaceutical dosage form.
  • the invention further encompasses a solid extended release pharmaceutical dosage form obtainable by a process as described herein.
  • the solid extended release pharmaceutical dosage form is preferably an oral dosage form. According to certain embodiments of the invention the solid extended release pharmaceutical dosage form is for use as a suppository.
  • extended release is defined for purposes of the present invention as to refer to products which are formulated to make the drug available over an extended period after ingestion thereby allowing a reduction in dosing frequency compared to a drug presented as a conventional dosage form (e.g. as a solution or an immediate release dosage form).
  • immediate release is defined for the purposes of the present invention as to refer to products which are formulated to allow the drug to dissolve in the gastrointestinal contents without substantial delay or prolongation of the dissolution or absorption of the drug.
  • solid oral extended release pharmaceutical dosage form for the purpose of the present invention refers to the administration form comprising a unit dose of active agent in extended release form such as an "extended release matrix formulation” and optionally other adjuvants and additives conventional in the art, such as a protective coating or a capsule and the like, and optionally any other additional features or components that are used in the dosage form.
  • solid oral extended release pharmaceutical dosage form refers to said dosage form in intact form i.e. prior to any tampering.
  • the extended release pharmaceutical dosage form can e.g. be a tablet comprising the extended release matrix formulation or a capsule comprising the extended release matrix formulation in the form of multi particulates.
  • the "extended release pharmaceutical dosage form” may comprise a portion of active agent in extended release form and another portion of active agent in immediate release form, e.g. as an immediate release layer of active agent surrounding the dosage form or an immediate release component included within the dosage form.
  • extended release matrix formulation is defined for purposes of the present invention as shaped solid form of a composition comprising at least one active agent and at least one extended release feature such as an extended release matrix material such as e.g. poly( ⁇ -caprolactone).
  • the composition can optionally comprise more than these two compounds namely further active agents and additional retardants and/or other materials, including but not limited to high molecular weight polyethylene oxides and other adjuvants and additives conventional in the art.
  • polyC ⁇ -caprolactone may for the purpose of the invention be abbreviated by PCL.
  • the molecular weight of "poly( ⁇ -caprolactone)" for the purpose of the present invention relates to a number average molecular weight.
  • Poly( ⁇ - caprolactone) is considered to have an approximate number average molecular weight of 10,000 when the viscosity is 400-1000 MPA at 25 degrees Celsius. Poly( ⁇ - caprolactone) is considered to have an approximate number average molecular weight of 37,000 when the melt flow index is 40g/10 minutes at 160 degrees Celsius and 2.16kg. Poly( ⁇ -caprolactone) is considered to have an approximate number average molecular weight of 42,500 when the melt flow index is 1.8 G/10 minutes at 80°C and 44 psi. Poly( ⁇ -caprolactone) is considered to have an approximate number average molecular weight of 80,000 when the melt flow index is 1.0 G/l 0 minutes at 80 degrees Celsius and 44 psi. .
  • polyethylene oxide may for the purpose of the invention be abbreviated by PEO.
  • PEO polyethylene oxide
  • Compositions with lower molecular weight are usually referred to as polyethylene glycols.
  • WO2008/023261 which is hereby incorporated by reference, describes pharmaceutical dosage forms prepared with PEO.
  • high molecular weight polyethylene oxide is defined for proposes of the present invention as having an approximate molecular weight of at least 1,000,000.
  • the approximate molecular weight is based on rheological measurements.
  • Polyethylene oxide is considered to have an approximate molecular weight of 1,000,000 when a 2% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 1, at 10 rpm, at 25 0 C shows a viscosity range of 400 to 800 mPa s (cP).
  • Polyethylene oxide is considered to have an approximate molecular weight of 2,000,000 when a 2% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 3, at 10 rpm, at 25°C shows a viscosity range of 2000 to 4000 mPa s (cP).
  • Polyethylene oxide is considered to have an approximate molecular weight of 4,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 1650 to 5500 mPa s (cP).
  • Polyethylene oxide is considered to have an approximate molecular weight of 5,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 5500 to 7500 mPa s (cP).
  • Polyethylene oxide is considered to have an approximate molecular weight of 7,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 7500 to 10,000 mPa s (cP).
  • Polyethylene oxide is considered to have an approximate molecular weight of 8,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 10,000 to 15,000 mPa s (cP).
  • Polyethylene oxide is considered to have an approximate molecular weight of 100,000 when a 5% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVT, spindle No.
  • polyethylene oxide is considered to have an approximate molecular weight of 900,000 when a 5% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 8800 to 17,600 mPa s (cP).
  • low molecular weight polyethylene oxide is defined for purposes of the present invention as having, based on the rheological measurements outlined above, an approximate molecular weight of less than 1,000,000.
  • melt formed is defined for the purpose of the invention to relate to a process wherein an at least partially molten mass is formed and shaped. It includes without being limited to formed by extrusion, formed by casting and formed by injection molding.
  • extrusion is defined for purposes of the present invention as referring to a process by which material is mixed and at least partially melted then forced through a die under controlled conditions.
  • casting is defined for purposes of the present invention as referring to a process by which molten material is poured into a mold of a desired shape or onto a surface.
  • injection molding is defined for purposed of the present invention as referring to a process by which molten material is injected under pressure into a mold.
  • direct compression is defined for purposes of the present invention as referring to a tableting process wherein the tablet or any other compressed dosage form is made by a process comprising the steps of dry blending the compounds and compressing the dry blend to form the dosage form, e.g. by using a diffusion blend and/or convection mixing process (e.g. Guidance for Industry, SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum).
  • a diffusion blend and/or convection mixing process e.g. Guidance for Industry, SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum.
  • dosage forms are regarded as "resistant to milling" when the respective dosage form provides after milling an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in- vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without milling.
  • dosage forms are regarded as "resistant to grinding" when the respective dosage form provides after grinding an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without grinding.
  • dosage forms are regarded as "resistant to alcohol extraction" when the respective dosage form provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol.
  • dosage forms are regarded as "resistant to milling and alcohol extraction" when the respective dosage form after milling provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol and without milling.
  • dosage forms are regarded as "resistant to grinding and alcohol extraction" when the respective dosage form after grinding provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C 5 characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol and without grinding.
  • SGF Simulated Gastric Fluid
  • SLS sodium lauryl sulfate
  • SGF sodium lauryl sulfate
  • active agent is defined as a pharmaceutically active substance which includes without limitation opioid analgesics.
  • opioid analgesic includes single compounds and combinations of compounds selected from the group of opioids and which provide an analgesic effect such as one single opioid agonist or a combination of opioid agonists, one single mixed opioid agonist-antagonist or a combination of mixed opioid agonist-antagonists, or one single partial opioid agonist or a combination of partial opioid agonists and combinations of an opioid agonists, mixed opioid agonist-antagonists and partial opioid agonists with one ore more opioid antagonists, stereoisomers, ether or ester, salts, hydrates and solvates thereof, compositions of any of the foregoing, and the like.
  • the present invention disclosed herein is specifically meant to encompass the use of the opioid analgesic in form of any pharmaceutically acceptable salt thereof.
  • Pharmaceutically acceptable salts include, but are not limited to, inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate and the like; organic acid salts such as formate, acetate, trifluoroacetate, maleate, tartrate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate, and the like; amino acid salts such as arginate, asparginate, glutamate and the like, and metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt and the like.
  • inorganic acid salts such as hydrochloride
  • the opioids used according to the present invention may contain one or more asymmetric centers and may give rise to enantiomers, diastereomers, or other stereoisomeric forms.
  • the present invention is also meant to encompass the use of all such possible forms as well as their racemic and resolved forms and compositions thereof.
  • the compounds described herein contain olef ⁇ nic double bonds or other centers of geometric asymmetry, it is intended to include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
  • stereoisomers is a general term for all isomers of individual molecules that differ only in the orientation of their atoms is space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
  • chiral center refers to a carbon atom to which four different groups are attached.
  • enantiomer or “enantiomeric” refers to a molecule that is nonsuperimposeable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction.
  • racemic refers to a mixture of equal parts of enantiomers and which is optically inactive.
  • resolution refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
  • Opioid agonists useful in the present invention include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethad
  • Opioid antagonists useful in combination with opioid agonists as described above are e.g. naloxone, naltrexone and nalmephene or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing, and the like.
  • a combination of oxycodone HCl and naloxone HCl in a ratio of about 2:1 is used.
  • ratios of oxycodone HCl : naloxone HCl are 5: 2.5, 10:5, 20:10, 30:15, 40:20, 60:30, 80:40, 100:50 and 120:60.
  • the opioid analgesic is selected from codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing, and the like.
  • the opioid analgesic is oxycodone, hydromorphone or oxymorphone or a salt thereof such as e.g. the hydrochloride.
  • the dosage form comprises from about 5 mg to about 500 mg oxycodone hydrochloride, from about 1 mg to about 100 mg hydromorphone hydrochloride or from about 5 mg to about 500 mg oxymorphone hydrochloride. If other salts, derivatives or forms are used, equimolar amounts of any other pharmaceutically acceptable salt or derivative or form including but not limited to hydrates and solvates or the free base may be used.
  • the dosage form may comprise e.g.
  • the dosage form may comprise e.g. 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 50 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg oxycodone hydrochloride or equimolar amounts of any other pharmaceutically acceptable salt, derivative or form including but not limited to hydrates and solvates or of the free base.
  • the dosage form may comprise e.g. 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 50 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg oxymorphone hydrochloride or equimolar amounts of any other pharmaceutically acceptable salt, derivative or form including but not limited to hydrates and solvates or of the free base.
  • the dosage form may comprise e.g. 2 mg, 4 mg, 5 mg, 8 mg, 12 mg, 15 mg, 16 mg, 24 mg, 25 mg, 32 mg, 48 mg, 50 mg, 64 mg or 75 mg hydromorphone hydrochloride or equimolar amounts of any other pharmaceutically acceptable salt, derivative or form including but not limited to hydrates and solvates or of the free base.
  • WO 2005/097801 Al, US 7,129,248 B2 and US 2006/0173029 Al describe a process for preparing oxycodone hydrochloride having a 14-hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm, more preferably of less than about 2 ppm, less than about 1 ppm, less than about 0.5 ppm or less than about 0.25 ppm.
  • ppm means "parts per million”.
  • ppm means parts per million of 14-hydroxycodeinone in a particular sample product.
  • the 14-hydroxycodeinone level can be determined by any method known in the art, preferably by HPLC analysis using UV detection.
  • oxycodone hydrochloride is used having a 14- hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm, more preferably of less than about 2 ppm, less than about 1 ppm, less than about 0.5 ppm or less than about 0.25 ppm.
  • therapeutically active agents may be used in accordance with the present invention, either in combination with opioids or instead of opioids.
  • therapeutically active agents include antihistamines (e.g., dimenhydrinate, diphenhydramine, chlorpheniramine and dexchlorpheniramine maleate), non -steroidal anti-inflammatory agents (e.g., naproxen, diclofenac, indomethacin, ibuprofen, sulindac, Cox-2 inhibitors) and acetaminophen, anti-emetics (e.g., metoclopramide, methylnaltrexone), anti- epileptics (e.g., phenytoin, meprobmate and nitrazepam), vasodilators (e.g., nifedipine, papaverine, diltiazem and nicardipine), anti-tussive agents and expectorants (e.g.
  • anti-asthmatics e.g. theophylline
  • antacids e.g. theophylline
  • anti-spasmodics e.g. atropine, scopolamine
  • antidiabetics e.g., insulin
  • diuretics e.g., ethacrynic acid, bendrofluthiazide
  • anti-hypotensives e.g., propranolol, clonidine
  • antihypertensives e.g., clonidine, methyldopa
  • bronchodilatiors e.g., albuterol
  • steroids e.g., hydrocortisone, triamcinolone, prednisone
  • antibiotics e.g., tetracycline
  • antihemorrhoidals hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants (e.
  • the invention is directed to the use of Cox-2 inhibitors as active agents, in combination with opioid analgesics or instead of opioid analgesics, for example the use of Cox-2 inhibitors such as meloxicam (4-hydroxy-2- methyl-iV-(5-methyl-2-thiazolyl)-2H-l,2-benzothiazine-3-carboxamide-l,l-dioxide), as disclosed in U.S. Serial No. 10/056,347 and 11/825,938, which are hereby incorporated by reference, nabumetone (4-(6-methoxy-2-naphthyl)-2-butanone), as disclosed in U.S. Serial No.
  • the present invention is also directed to the dosage forms utilizing active agents such as for example, benzodiazepines, barbiturates or stimulants such as amphetamines. These may be combined with the respective antagonists.
  • active agents such as for example, benzodiazepines, barbiturates or stimulants such as amphetamines.
  • benzodiazepines refers to benzodiazepines and drugs that are derivatives of benzodiazepine that are able to depress the central nervous system.
  • Benzodiazepines include, but are not limited to, alprazolam, bromazepam, chlordiazepoxide, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, methylphenidate as well as pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof.
  • Benzodiazepine antagonists that can be used in the present invention include, but are not limited to, flumazenil as well as pharmaceutically acceptable salts, hydrates, and solvates.
  • Barbiturates refer to sedative-hypnotic drugs derived from barbituric acid
  • Barbiturates include, but are not limited to, amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital and as well as pharmaceutically acceptable salts, hydrates, and solvates mixtures thereof.
  • Barbiturate antagonists that can be used in the present invention include, but are not limited to, amphetamines as well as pharmaceutically acceptable salts, hydrates, and solvates.
  • Stimulants refer to drugs that stimulate the central nervous system.
  • Stimulants include, but are not limited to, stimulants such as amphetamines, such as amphetamine, dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate as well as pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof.
  • Stimulant antagonists that can be used in the present invention include, but are not limited to, benzodiazepines, as well as pharmaceutically acceptable salts, hydrates, and solvates as described herein.
  • Fig. 1 to 14-1 depict the dissolution profiles of the respective Examples 1 to 14 as described below.
  • Fig .14-2 depicts the intact (a), milled (b) and grinded(c) multiparticulates of Example 14
  • Fig. 14-3 depicts the multiparticulates of Example 14 after milling in a coffee mill (a) and a comparison tablet after milling in a coffee mill (b).
  • the invention relates to a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly( ⁇ - caprolactone), and at least one active agent.
  • poly( ⁇ -caprolactone) is a suitable polymeric material for forming an extended release matrix formulation which can provide a wide variety of release profiles when used in the form of melt formed multi particulates.
  • the melt forming according to the invention can be accomplished by several methods, including extrusion, casting and injection molding.
  • the multi particulates have preferably a diameter in the range of about 0.1 to about 3 mm.
  • poly( ⁇ -caprolactone) due to its specific polymer characteristics, imparts a milling and/or grinding resistance to the extended release formulation in that the multi particles comprising poly( ⁇ -caprolactone) do not form during milling and/or grinding smaller individual particles but in case of milling tend to fuse/melt together forming a lumpy mass and in case of grinding might deform.
  • Figures 14-2 and 14-3 It is believed that the release of the active agent does therefore not substantially change upon milling or grinding. In some cases the release is even slowed down. Thereby the extended release dosage form comprising said multi particulates is rendered less attractive for abuse.
  • At least one poly( ⁇ - caprolactone) with an approximate number average molecular weight of at least about 6,000 is used.
  • the at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of at least about 10,000.
  • the at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of at least about 20,000.
  • the at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of at least about 25,000.
  • the at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of at least about 37,000.
  • the at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of about 42,500. According to certain embodiments of the invention the at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of at least about 80,000. According to further certain embodiments of the invention, the at least one poly( ⁇ -caprolactone) has an approximate number average molecular weight of between about 6,000 to about 80,000, or between about 10,000 and about 80,000, or between about 20,000 and about 80,000, or between about 25,000 and about 80,000or between about 37,000 and about 80,000, or between about 42,500 and about 80,000.
  • the extended release matrix formulation comprises at least two poly( ⁇ -caprolactone) with an approximate number average molecular weight of between about 6,000 and about 25,000 and between about 37,000 and about 80,000, or between about 10,000 and about 25,000 and between about 37,000 and about 80,000, or between about 10,000 and about 25,000 and between about 42,500 and about 80,000.
  • the overall content of poly( ⁇ -caprolactone) is at least about 50 weight-%, or at least about 60 weight-%, or at least about 70 weight-%, or at least about 80 weight-%, or at least about 90 weight-%, or between about 50 and about 90 weight-%, or between about 60 and about 90 weight-%, or between about 70 and about 90 weight-%, or between about 80 and about 90 weight-% of the extended release matrix formulation.
  • the extended release matrix formulation comprises least one poly( ⁇ -caprolactone) with an approximate number average molecular weight of between about 37,000 and about 80,000 which is present at an amount of between about 50 and about 90 weight-% of the extended release matrix formulation.
  • the extended release matrix formulation comprises further at least one polyethylene glycol, which may be present at an amount of between about 1 and about 20 or about 1 and about 15 weight-%.
  • the extended release matrix formulation comprises further at least one high molecular weight polyethylene oxide with an approximate molecular weight of between about 1,000,000 and about 10,00O 5 OOO, based on rheological measurements. It is the finding of the inventors that the combination of poly( ⁇ -caprolactone) and high molecular polyethylene oxide provide a resistance to milling and/or grinding in combination with a resistance to alcohol extraction thereby rendering the dosage form less attractive for illicit use and rendering the dosage form safer when used in combination with alcohol.
  • the high molecular weight polyethylene oxide may be present at an amount of between about 5 and about 35 weight-%.
  • the high molecular weight polyethylene oxide used has been screened through a screen with a size of 15/100 of the average diameter of the resulting melt formed multi particulate extended release formulation. According to certain embodiments the high molecular weight polyethylene oxide used has been screened with a 100 US mesh screen.
  • the extended release matrix formulation further comprises at least one poloxamer.
  • the extended release matrix formulations may comprise further any other ingredients/excipients as conventional in the art.
  • the active agent is an opioid analgesic, in particular selected from the group of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine
  • the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
  • the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride or in particular comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 50 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg of oxycodone hydrochloride.
  • the oxycodone hydrochloride has a 14-hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm, or even less than 1 ppm.
  • the opioid analgesic is oxymorphone hydrochloride and the dosage form comprises from about 1 mg to about 500 mg of oxymorphone hydrochloride, in particular 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 50mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg of oxymorphone hydrochloride.
  • the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from about 1 mg to about 100 mg of hydromorphone hydrochloride, in particular 2 mg, 4 mg, 5 mg, 8 mg, 12 mg, 15 mg, 16 mg, 24 mg, 25 mg, 32 mg, 48 mg 50 mg, 64 mg or 75 mg of hydromorphone hydrochloride.
  • the dosage form contains active in immediate release form, wherein the same or different active agents are in extended release and in immediate release form.
  • the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C, between about 12.5 % and about 55 % (by wt) active agent released after 1 hour, between about 25 % and about 65 % (by wt) active agent released after 2 hours, between about 45 % and about 85 % (by wt) active agent released after 4 hours and between about 55 % and about 95 % (by wt) active agent released after 6 hours.
  • the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C between about 10 % and about 30% (by wt) active agent released after 2 hour, about 40 % and about 75 % (by wt) active agent released after 8 hours and no less than about 80%(by wt) active agent released after 22 hours.
  • the dosage form provides an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points or no more than about 10 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol.
  • the dosage form provides after milling an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that increases no more than about 20 % points or no more than 10 % points or even decreases when compared to the corresponding in- vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without milling.
  • the dosage form provides after grinding an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that increases no more than about 20 % points or more than about 10 % points or even decreases when compared to the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without grinding.
  • the dosage form after milling provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points or no more than 10 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without ethanol at 37° C without milling.
  • the dosage form after grinding provides an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid, comprising 40% ethanol, at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points or no more than 10 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without ethanol at 37° C without grinding.
  • the active agent is oxycodone hydrochloride, hydromorphone hydrochloride or oxymorphone hydrochloride.
  • the dosage forms as described herein are used in a method of treating pain in a patient in need thereof, wherein the dosage form comprises an opioid analgesic and the use of such a dosage form for the manufacture of a medicament for the treatment of pain.
  • poly( ⁇ -caprolactone) is used as matrix forming material in the manufacture of a solid extended release oral dosage form comprising an active agent selected from opioids for imparting to the solid extended release oral dosage form resistance to milling and/or grinding.
  • a process of preparing a solid oral extended release pharmaceutical dosage form comprising the steps of:
  • a process of preparing a solid oral extended release pharmaceutical dosage form comprising the steps of:
  • Extruding the screened and blended materials in a twin screw extruder fitted with a die and set on counter-rotation with zone (barrel) temperatures ranged from about 18°C to about 110°C to obtain strands with a
  • the polyethylene oxide may be screened through a # 100 US mesh screen
  • the solid oral extended release pharmaceutical dosage form is obtainable by a process as described above.
  • composition of the poly( ⁇ -caprolactone) multiparticulates is summarized in Table 1 below.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
  • the poly( ⁇ -caprolactone) pellets were difficult to grind and fused/melted during milling.
  • composition of the poly( ⁇ -caprolactone) multiparticulates is summarized in Table 2 below.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling time - every minute up to 1440 minutes.
  • Rotor Shaft Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute
  • the poly( ⁇ -caprolactone) pellets were difficult to grind but did not fuse/melt during milling.
  • composition of the poly( ⁇ -caprolactone) multi particulates is summarized in Table 3 below.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • Thermodyne Hot Plate (temperature range 90° - 16O 0 C) until mixture appeared homogeneous.
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling time - every minute up to 1440 minutes.
  • the poly( ⁇ -caprolactone) pellets were difficult to grind and fused/melted during milling.
  • composition of the poly( ⁇ -caprolactone) multiparticulates is summarized in Table 4 below.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
  • Chamber Volume 80 ml Blade: Stainless steel beater 1.4034
  • the polyC ⁇ -caprolactone pellets were difficult to grind but did not fuse/melt during milling.
  • composition of this poly( ⁇ -caprolactone) multiparticulate formulation is summarized in Table 5.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37 0 C.
  • Milling Chamber Stainless steel
  • the poly( ⁇ -caprolactone) pellets were tough. The pellets did not fuse/melt during milling. Table 5b
  • composition of this poly( ⁇ -caprolactone) multiparticulate formulation is summarized in Table 6.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • PCL high moleculare weight polycaprolactne
  • PCL high moleculare weight polycaprolactne
  • BHT milled BHT
  • Thermodyne Hot Plate (temperature range 90° - 16O 0 C) until mixture appeared homogeneous.
  • Apparatus- USP Type I Baskets
  • Sampling time every minute up to 1440 minutes.
  • the poly( ⁇ -caprolactone) pellets were tough and difficult to grind. During milling the discrete matrix particles formed a single fused mass.
  • composition of this poly( ⁇ -caprolactone) multiparticulate formulation is summarized in Table 7.
  • Apparatus- USP Type I Baskets
  • Chamber Volume 80 ml Blade: Stainless steel beater 1.4034
  • composition of this poly( ⁇ -caprolactone) multiparticulate formulation is summarized in Table 8.
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
  • SLS Sulfate
  • EtOH Simulated Gastric Fluid with 40% ethanol
  • Milling Chamber Stainless steel Chamber Volume: 80 ml
  • the poly( ⁇ -caprolactone) pellets were difficult to grind and fused/melted during milling.
  • composition of this poly( ⁇ -caprolactone) multiparticulate formulation is summarized in Table 9.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • Thermodyne Hot Plate (temperature range 90° - 16O 0 C) until mixture appeared homogeneous.
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling time - every minute up to 1440 minutes.
  • Blade Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W
  • the poly( ⁇ -caprolactone) pellets were difficult to grind and fused/melted during milling.
  • composition of this poly( ⁇ -caprolactone) multiparticulate formulation is summarized in Table 10.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37 0 C. 2. Sampling time - every minute up to 1440 minutes.
  • Milling Chamber Stainless steel
  • Motor rating input 160 W
  • Motor rating output 100 W
  • the poly( ⁇ -caprolactone) pellets were difficult to grind and fused/melted during milling.
  • the dissolution results for milled samples are summarized in Figure 10a and Table 10b.
  • the processing steps for manufacturing the poly( ⁇ -caprolactone) multiparticulates are as follows:
  • PCL/PEO/BHT PCL/PEO/BHT and mixed on a Thermodyne Hot Plate (temperature range 90° - 16O 0 C) until the mixture appeared homogeneous. 5.
  • Casting The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
  • Pelletizing The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37 0 C. 2. Sampling time - every minute up to 1440 minutes.
  • Rotor Shaft Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute
  • composition of the poly( ⁇ -caprolactone) melt extruded multiparticulates is summarized in Table 12 below.
  • Torque 97 Melt Pressure (psi): 1930 Feed rate (g/min.): 20 Screw speed (rpm): 66 Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
  • BHT were screened through a # 20 US mesh screen. 2. Blending: The materials screened in Step 1 were loaded into an 8 qt. V- blender QA Poly( ⁇ -caprolactone), Naltrexone HCl 5 Polyethylene oxide, BHT and 1 A Poly( ⁇ -caprolactone)) and blended for 10 minutes at ambient temperature.
  • Extrusion Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into approximately 1 mm strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 18°C to 88°C.
  • Cooling The strands were cooled on a conveyor at ambient temperature.
  • Pelletizing The cooled strands were cut into pellets approximately 1 mm in length.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37 0 C.
  • Chamber Volume 80 ml Blade: Stainless steel beater 1.4034
  • the poly( ⁇ -caprolactone) pellets were difficult to crush with a mortar and pestle. They fused/melted during milling but incomplete after 15 seconds.
  • composition of the Poly( ⁇ -caprolactone) melt extruded multiparticulates is summarized in Table 13 below.
  • Torque (%): 62 Melt Pressure (psi) 370 Feed rate (g/min.): 22 Screw speed (rpm): 50 Melt Temp. ( 0 C): 89
  • Blending The materials screened in Step 1 were loaded into an 8 qt. V-blender QA Poly( ⁇ -caprolactone), Naltrexone HCl, Polyethylene oxide, polyethylene glycol, BHT and 1 A Poly( ⁇ -caprolactone)) and blended for 10 minutes at ambient temperature.
  • Extrusion Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 18°C to 110°C.
  • Cooling The strands were cooled on a conveyor at ambient temperature. 5.
  • Pelletizing The cooled strands were cut into pellets approximately 1.0 mm, 1.5 mm and 2.0 mm in length for Sample #3, Sample #4 and Sample #1, respectively.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
  • Milling Chamber Stainless steel Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute
  • Feed rate (g/min.): 20-22
  • Blending The materials screened in Step 1 were loaded into a 16 qt. V-blender (/4 Poly( ⁇ -caprolactone), Oxycodone HCl, Polyethylene oxide, polyethylene glycol, BHT and 1 A Poly( ⁇ -caprolactone)) and blended for 10 minutes at ambient temperature.
  • V-blender /4 Poly( ⁇ -caprolactone), Oxycodone HCl, Polyethylene oxide, polyethylene glycol, BHT and 1 A Poly( ⁇ -caprolactone)
  • Extrusion Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 14°C to 90°C. 4. Cooling: The strands were cooled on a conveyor at ambient temperature.
  • Apparatus- USP Type I (Baskets), 100 rpm at 37 0 C. 2. Sampling time - every minute up to 1440 minutes.
  • Extraction Solvent 1 :2 mixture acetonitrile and simulated gastric fluid without enzymes (SGF).
  • Oxycodone N-oxide is the only known degradation product included in the % total degradation products.
  • Noroxymorphone, oxymorphone, 10-hydroxyoxycodone, 6- ⁇ -oxycodol, 7,8-hydro-8, 14-dihydroxycodeinone, and hydrocodone which are known process impurities can be identified with this method but are not included in the calculation of % total degradation products.
  • Extraction Solvent 1 :2 mixture acetonitrile and simulated gastric fluid without enzymes (SGF).
  • Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling Time- Generally, 1 hour, 2 hrs., 4 hrs., 8hrs., 12 hrs., 18 hrs. and 24 hrs.

Abstract

The present invention relates to pharmaceutical dosage forms, for example to pharmaceutical dosage forms comprising poly(ε-caprolactone), and processes of manufacture, uses, and methods of treatment thereof.

Description

PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY (ε-CAPROLACTONE)
TECHNICAL FIELD OF THE INVENTION
[001] The present invention relates to pharmaceutical dosage forms, for example pharmaceutical dosage forms comprising poly(ε-caprolactone), and processes of manufacture, uses, and methods of treatment thereof.
BACKGROUND OF THE INVENTION
[002] Extended release oral dosage forms allow a specific release of active agent over an extended period of time. Larger dosing intervals, e.g. twice- or once-a- day dosing, may provide fewer side effects and overall better patient compliance.
[003] Pharmaceutical products and in particular extended release dosage forms which usually comprise a larger amount of active agent in a single dose are increasingly the subject of abuse. For example, a particular dose of opioid agonist may be more potent when administered parenterally as compared to the same dose administered orally. Some formulations can be tampered with to provide the opioid agonist contained therein for illicit use. Controlled release opioid agonist formulations are sometimes milled or ground, and/or subject to extraction with solvents (e.g., ethanol) by drug abusers to provide the opioid contained therein for immediate release upon oral or parenteral administration.
[004] Extended release opioid agonist dosage forms which can liberate a portion of the opioid upon exposure to ethanol, can also result in a patient receiving the dose more rapidly than intended if a patient concomitantly uses alcohol with the dosage form. [005] There continues to exist a need in the art for extended release pharmaceutical oral dosage forms. In particular there continues to exist a need for such dosage forms that resist illicit use and are safe when concomitantly used with alcohol.
OBJECTS AND SUMMARY OF THE INVENTION
[006] It is an object of certain embodiments of the present invention to provide an extended release dosage form comprising poly(ε-caprolactone).
[007] It is a further object of certain embodiments of the present invention to provide a solid tamper resistant oral extended release dosage form which is resistant to milling.
[008] It is a further obj ect of certain embodiments of the present invention to provide a solid extended release dosage form which is resistant to milling, resistant to grinding and resistant to alcohol extraction.
[009] It is a further obj ect of certain embodiments of the present invention to provide the above dosage forms comprising an opioid analgesic.
[0010] According to certain embodiments the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent.
[0011] According to certain embodiments the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent, wherein at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least 10,000.
[0012] According to certain embodiments the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent, wherein poly(ε-caprolactone) is present at an amount of at least about 50 weight-% of the extended release matrix formulation.
[0013] According to certain embodiments the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent, wherein the multi particulates have a diameter in the range of about 0.1 to about 3 mm.
[0014] According to certain embodiments the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent, and additionally comprising at least one high molecular weight polyethylene oxide.
[0015] According to certain embodiments the invention encompasses a solid extended release pharmaceutical dosage form as described in the above paragraphs, wherein the active agent is an opioid analgesic, in particular selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, and mixtures of any of the foregoing.
[0016] According to certain embodiments the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent, wherein the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C, between 12.5 % and 55 % (by wt) active agent released after 1 hour, between 25 % and 65 % (by wt) active agent released after 2 hours, between 45 % and 85 % (by wt) active agent released after 4 hours and between 55 % and 95 % (by wt) active agent released after 6 hours. These dosage forms comprise in particular oxycodone hydrochloride, hydromorphone hydrochloride, morphine sulfate or oxymorphone hydrochloride in the active agent.
[0017] According to certain other embodiments the invention encompasses a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent, wherein the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C between 10 % and 30% (by wt) active agent released after 2 hour, 40 % and 75 % (by wt) active agent released after 8 hours and no less than 80%(by wt) active agent released after 22 hours.
[0018] The invention further encompasses a method of treatment wherein a dosage form comprising an opioid analgesic as described herein is administered for treatment of pain to a patient in need thereof. [0019] The invention further encompasses the use of a dosage form comprising an opioid analgesic as described herein for the manufacture of a medicament for the treatment of pain.
[0020] The invention further encompasses the use of poly(ε-caprolactone) as matrix forming material in the manufacture of a solid extended release dosage form comprising an active agent selected from opioids for imparting to the solid extended release dosage form resistance to milling.
[0021] The invention further encompasses a process of preparing a solid extended release pharmaceutical dosage form.
[0022] The invention further encompasses a solid extended release pharmaceutical dosage form obtainable by a process as described herein.
[0023] According to the invention the solid extended release pharmaceutical dosage form is preferably an oral dosage form. According to certain embodiments of the invention the solid extended release pharmaceutical dosage form is for use as a suppository.
[0024] The term "extended release" is defined for purposes of the present invention as to refer to products which are formulated to make the drug available over an extended period after ingestion thereby allowing a reduction in dosing frequency compared to a drug presented as a conventional dosage form (e.g. as a solution or an immediate release dosage form).
[0025] The term "immediate release" is defined for the purposes of the present invention as to refer to products which are formulated to allow the drug to dissolve in the gastrointestinal contents without substantial delay or prolongation of the dissolution or absorption of the drug.
[0026] The term "solid oral extended release pharmaceutical dosage form" for the purpose of the present invention refers to the administration form comprising a unit dose of active agent in extended release form such as an "extended release matrix formulation" and optionally other adjuvants and additives conventional in the art, such as a protective coating or a capsule and the like, and optionally any other additional features or components that are used in the dosage form. Unless specifically indicated the term "solid oral extended release pharmaceutical dosage form" refers to said dosage form in intact form i.e. prior to any tampering. The extended release pharmaceutical dosage form can e.g. be a tablet comprising the extended release matrix formulation or a capsule comprising the extended release matrix formulation in the form of multi particulates. The "extended release pharmaceutical dosage form" may comprise a portion of active agent in extended release form and another portion of active agent in immediate release form, e.g. as an immediate release layer of active agent surrounding the dosage form or an immediate release component included within the dosage form.
[0027] The term "extended release matrix formulation" is defined for purposes of the present invention as shaped solid form of a composition comprising at least one active agent and at least one extended release feature such as an extended release matrix material such as e.g. poly(ε-caprolactone). The composition can optionally comprise more than these two compounds namely further active agents and additional retardants and/or other materials, including but not limited to high molecular weight polyethylene oxides and other adjuvants and additives conventional in the art. [0028] The term "polyCε-caprolactone) "may for the purpose of the invention be abbreviated by PCL. The molecular weight of "poly(ε-caprolactone)" for the purpose of the present invention relates to a number average molecular weight. Poly(ε- caprolactone) is considered to have an approximate number average molecular weight of 10,000 when the viscosity is 400-1000 MPA at 25 degrees Celsius. Poly(ε- caprolactone) is considered to have an approximate number average molecular weight of 37,000 when the melt flow index is 40g/10 minutes at 160 degrees Celsius and 2.16kg. Poly(ε-caprolactone) is considered to have an approximate number average molecular weight of 42,500 when the melt flow index is 1.8 G/10 minutes at 80°C and 44 psi. Poly(ε-caprolactone) is considered to have an approximate number average molecular weight of 80,000 when the melt flow index is 1.0 G/l 0 minutes at 80 degrees Celsius and 44 psi. .
[0029] The term "polyethylene oxide" may for the purpose of the invention be abbreviated by PEO. Preferably it has a molecular weight of at least 25,000, measured as is conventional in the art, and more preferably having a molecular weight of at least 100,000. Compositions with lower molecular weight are usually referred to as polyethylene glycols. WO2008/023261, which is hereby incorporated by reference, describes pharmaceutical dosage forms prepared with PEO.
[0030] The term "high molecular weight polyethylene oxide" is defined for proposes of the present invention as having an approximate molecular weight of at least 1,000,000. For the purpose of this invention the approximate molecular weight is based on rheological measurements. Polyethylene oxide is considered to have an approximate molecular weight of 1,000,000 when a 2% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 1, at 10 rpm, at 250C shows a viscosity range of 400 to 800 mPa s (cP). Polyethylene oxide is considered to have an approximate molecular weight of 2,000,000 when a 2% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 3, at 10 rpm, at 25°C shows a viscosity range of 2000 to 4000 mPa s (cP). Polyethylene oxide is considered to have an approximate molecular weight of 4,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 1650 to 5500 mPa s (cP). Polyethylene oxide is considered to have an approximate molecular weight of 5,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 5500 to 7500 mPa s (cP). Polyethylene oxide is considered to have an approximate molecular weight of 7,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 7500 to 10,000 mPa s (cP). Polyethylene oxide is considered to have an approximate molecular weight of 8,000,000 when a 1% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 10,000 to 15,000 mPa s (cP). Regarding the lower molecular weight polyethylene oxides; Polyethylene oxide is considered to have an approximate molecular weight of 100,000 when a 5% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVT, spindle No. 1, at 50 rpm, at 25°C shows a viscosity range of 30 to 50 mPa s (cP) and polyethylene oxide is considered to have an approximate molecular weight of 900,000 when a 5% (by wt) aqueous solution of said polyethylene oxide using a Brookfield viscometer Model RVF, spindle No. 2, at 2 rpm, at 25°C shows a viscosity range of 8800 to 17,600 mPa s (cP).
[0031] The term "low molecular weight polyethylene oxide" is defined for purposes of the present invention as having, based on the rheological measurements outlined above, an approximate molecular weight of less than 1,000,000. [0032] The term "melt formed" is defined for the purpose of the invention to relate to a process wherein an at least partially molten mass is formed and shaped. It includes without being limited to formed by extrusion, formed by casting and formed by injection molding.
[0033] The term "extrusion" is defined for purposes of the present invention as referring to a process by which material is mixed and at least partially melted then forced through a die under controlled conditions.
[0034] The term "casting" is defined for purposes of the present invention as referring to a process by which molten material is poured into a mold of a desired shape or onto a surface.
[0035] The term "injection molding" is defined for purposed of the present invention as referring to a process by which molten material is injected under pressure into a mold.
[0036] The term "direct compression" is defined for purposes of the present invention as referring to a tableting process wherein the tablet or any other compressed dosage form is made by a process comprising the steps of dry blending the compounds and compressing the dry blend to form the dosage form, e.g. by using a diffusion blend and/or convection mixing process (e.g. Guidance for Industry, SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum).
[0037] For the purpose of certain embodiments of the present invention dosage forms are regarded as "resistant to milling" when the respective dosage form provides after milling an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in- vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without milling.
[0038] For the purpose of certain embodiments of the present invention dosage forms are regarded as "resistant to grinding" when the respective dosage form provides after grinding an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without grinding.
[0039] For the purpose of certain embodiments of the present invention dosage forms are regarded as "resistant to alcohol extraction" when the respective dosage form provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol.
[0040] For the purpose of certain embodiments of the present invention dosage forms are regarded as "resistant to milling and alcohol extraction" when the respective dosage form after milling provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol and without milling.
[0041] For the purpose of certain embodiments of the present invention dosage forms are regarded as "resistant to grinding and alcohol extraction" when the respective dosage form after grinding provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C5 characterized by the percent amount of active released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol and without grinding.
[0042] The term "milling" refers to the following procedure
Number of doses: 2 Duration of Milling: 15 seconds
Milling machine: IKA Al 1 Basic Impact Mill
Milling Chamber: Stainless steel
Chamber Volume: 80 ml
Blade: Stainless steel Beater: Stainless steell.4034
Rotor Shaft: Stainless steel 1.4571
Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute Circuniferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W For demonstration purposes only and irrelevant for the definition of milling resistance, milling can also be performed in a coffee mill. For demonstration sake Figure 14-3 shows the multi particulates of the present invention and a comparison tablet after milling in a coffee mill.
[0043] The term "grinding" refers to the following procedure:
Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2 Duration of grinding: 20 rotations
[0044] The term "Simulated Gastric Fluid" (SGF) relates to Simulated Gastric
Fluid without enzymes and either without sodium lauryl sulfate (SLS), with 0.5% sodium lauryl sulfate or 0.1% sodium lauryl sulfate. The term "Simulated Gastric Fluid with 40% Ethanol" relates to SGF with 40% Ethanol and without enzymes and without sodium lauryl sulfate.
[0045] For the purpose of the present invention the term "active agent" is defined as a pharmaceutically active substance which includes without limitation opioid analgesics.
[0046] For purposes of the present invention, the term "opioid analgesic" includes single compounds and combinations of compounds selected from the group of opioids and which provide an analgesic effect such as one single opioid agonist or a combination of opioid agonists, one single mixed opioid agonist-antagonist or a combination of mixed opioid agonist-antagonists, or one single partial opioid agonist or a combination of partial opioid agonists and combinations of an opioid agonists, mixed opioid agonist-antagonists and partial opioid agonists with one ore more opioid antagonists, stereoisomers, ether or ester, salts, hydrates and solvates thereof, compositions of any of the foregoing, and the like.
[0047] The present invention disclosed herein is specifically meant to encompass the use of the opioid analgesic in form of any pharmaceutically acceptable salt thereof.
[0048] Pharmaceutically acceptable salts include, but are not limited to, inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate and the like; organic acid salts such as formate, acetate, trifluoroacetate, maleate, tartrate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate, and the like; amino acid salts such as arginate, asparginate, glutamate and the like, and metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt and the like.
[0049] The opioids used according to the present invention may contain one or more asymmetric centers and may give rise to enantiomers, diastereomers, or other stereoisomeric forms. The present invention is also meant to encompass the use of all such possible forms as well as their racemic and resolved forms and compositions thereof. When the compounds described herein contain olefϊnic double bonds or other centers of geometric asymmetry, it is intended to include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
[0050] As used herein, the term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms is space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
[0051] The term "chiral center" refers to a carbon atom to which four different groups are attached.
[0052] The term "enantiomer" or "enantiomeric" refers to a molecule that is nonsuperimposeable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction.
[0053] The term "racemic" refers to a mixture of equal parts of enantiomers and which is optically inactive.
[0054] The term "resolution" refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
[0055] Opioid agonists useful in the present invention include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing, and the like.
[0056] Opioid antagonists useful in combination with opioid agonists as described above are e.g. naloxone, naltrexone and nalmephene or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing, and the like.
[0057] In certain embodiments e.g. a combination of oxycodone HCl and naloxone HCl in a ratio of about 2:1 is used. Examples for ratios of oxycodone HCl : naloxone HCl are 5: 2.5, 10:5, 20:10, 30:15, 40:20, 60:30, 80:40, 100:50 and 120:60.
[0058] In certain embodiments, the opioid analgesic is selected from codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing, and the like.
[0059] In certain embodiments, the opioid analgesic is oxycodone, hydromorphone or oxymorphone or a salt thereof such as e.g. the hydrochloride. The dosage form comprises from about 5 mg to about 500 mg oxycodone hydrochloride, from about 1 mg to about 100 mg hydromorphone hydrochloride or from about 5 mg to about 500 mg oxymorphone hydrochloride. If other salts, derivatives or forms are used, equimolar amounts of any other pharmaceutically acceptable salt or derivative or form including but not limited to hydrates and solvates or the free base may be used. The dosage form may comprise e.g. 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 50 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg oxycodone hydrochloride or equimolar amounts of any other pharmaceutically acceptable salt, derivative or form including but not limited to hydrates and solvates or of the free base. The dosage form may comprise e.g. 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 50 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg oxymorphone hydrochloride or equimolar amounts of any other pharmaceutically acceptable salt, derivative or form including but not limited to hydrates and solvates or of the free base. The dosage form may comprise e.g. 2 mg, 4 mg, 5 mg, 8 mg, 12 mg, 15 mg, 16 mg, 24 mg, 25 mg, 32 mg, 48 mg, 50 mg, 64 mg or 75 mg hydromorphone hydrochloride or equimolar amounts of any other pharmaceutically acceptable salt, derivative or form including but not limited to hydrates and solvates or of the free base.
[0060] WO 2005/097801 Al, US 7,129,248 B2 and US 2006/0173029 Al, all of which are hereby incorporated by reference, describe a process for preparing oxycodone hydrochloride having a 14-hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm, more preferably of less than about 2 ppm, less than about 1 ppm, less than about 0.5 ppm or less than about 0.25 ppm.
[0061] The term "ppm" as used herein means "parts per million". Regarding 14- hydroxycodeinone, "ppm" means parts per million of 14-hydroxycodeinone in a particular sample product. The 14-hydroxycodeinone level can be determined by any method known in the art, preferably by HPLC analysis using UV detection.
[0062] In certain embodiments of the present invention, wherein the active agent is oxycodone hydrochloride, oxycodone hydrochloride is used having a 14- hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm, more preferably of less than about 2 ppm, less than about 1 ppm, less than about 0.5 ppm or less than about 0.25 ppm.
[0063] In certain other embodiments other therapeutically active agents may be used in accordance with the present invention, either in combination with opioids or instead of opioids. Examples of such therapeutically active agents include antihistamines (e.g., dimenhydrinate, diphenhydramine, chlorpheniramine and dexchlorpheniramine maleate), non -steroidal anti-inflammatory agents (e.g., naproxen, diclofenac, indomethacin, ibuprofen, sulindac, Cox-2 inhibitors) and acetaminophen, anti-emetics (e.g., metoclopramide, methylnaltrexone), anti- epileptics (e.g., phenytoin, meprobmate and nitrazepam), vasodilators (e.g., nifedipine, papaverine, diltiazem and nicardipine), anti-tussive agents and expectorants (e.g. codeine phosphate), anti-asthmatics (e.g. theophylline), antacids, anti-spasmodics (e.g. atropine, scopolamine), antidiabetics (e.g., insulin), diuretics (e.g., ethacrynic acid, bendrofluthiazide), anti-hypotensives (e.g., propranolol, clonidine), antihypertensives (e.g., clonidine, methyldopa), bronchodilatiors (e.g., albuterol), steroids (e.g., hydrocortisone, triamcinolone, prednisone), antibiotics (e.g., tetracycline), antihemorrhoidals, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants (e.g. pseudoephedrine ), laxatives, vitamins, stimulants (including appetite suppressants such as phenylpropanolamine) and cannabinoids, as well as pharmaceutically acceptable salts, hydrates, and solvates of the same.
[0064] In certain embodiments, the invention is directed to the use of Cox-2 inhibitors as active agents, in combination with opioid analgesics or instead of opioid analgesics, for example the use of Cox-2 inhibitors such as meloxicam (4-hydroxy-2- methyl-iV-(5-methyl-2-thiazolyl)-2H-l,2-benzothiazine-3-carboxamide-l,l-dioxide), as disclosed in U.S. Serial No. 10/056,347 and 11/825,938, which are hereby incorporated by reference, nabumetone (4-(6-methoxy-2-naphthyl)-2-butanone), as disclosed in U.S. Serial No. 10/056,348, which is hereby incorporated by reference, celecoxib (4- [5 -(4-methylphenyl)-3 -(trifluoromethyl)- 1 H-pyrazol- 1 - yljbenzenesulfonamide), as disclosed in U.S. Serial No. 11/698,394, which is hereby incorporated by reference, nimesulide (N-(4-Nitro-2- phenoxyphenyl)methanesulfonamide), as disclosed in U.S. Serial No. 10/057,630, which is hereby incorporated by reference, and N-[3-(formylamino)-4-oxo-6- phenoxy-4H-l-benzopyran-7-yl] methanesulfonamide (T-614), as disclosed in U.S. Serial No. 10/057,632, which is hereby incorporated by reference.
[0065] The present invention is also directed to the dosage forms utilizing active agents such as for example, benzodiazepines, barbiturates or stimulants such as amphetamines. These may be combined with the respective antagonists.
[0066] The term "benzodiazepines" refers to benzodiazepines and drugs that are derivatives of benzodiazepine that are able to depress the central nervous system. Benzodiazepines include, but are not limited to, alprazolam, bromazepam, chlordiazepoxide, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, methylphenidate as well as pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof. Benzodiazepine antagonists that can be used in the present invention include, but are not limited to, flumazenil as well as pharmaceutically acceptable salts, hydrates, and solvates.
[0067] Barbiturates refer to sedative-hypnotic drugs derived from barbituric acid
(2, 4, 6-trioxohexahydropyrimidine). Barbiturates include, but are not limited to, amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital and as well as pharmaceutically acceptable salts, hydrates, and solvates mixtures thereof. Barbiturate antagonists that can be used in the present invention include, but are not limited to, amphetamines as well as pharmaceutically acceptable salts, hydrates, and solvates.
[0068] Stimulants refer to drugs that stimulate the central nervous system. Stimulants include, but are not limited to, stimulants such as amphetamines, such as amphetamine, dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate as well as pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof. Stimulant antagonists that can be used in the present invention include, but are not limited to, benzodiazepines, as well as pharmaceutically acceptable salts, hydrates, and solvates as described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0069] Fig. 1 to 14-1 depict the dissolution profiles of the respective Examples 1 to 14 as described below.
[0070] Fig .14-2 depicts the intact (a), milled (b) and grinded(c) multiparticulates of Example 14 [0071] Fig. 14-3 depicts the multiparticulates of Example 14 after milling in a coffee mill (a) and a comparison tablet after milling in a coffee mill (b).
DETAILED DESCRIPTION
[0072] According to certain embodiments the invention relates to a solid extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε- caprolactone), and at least one active agent.
[0073] The inventors have found that poly(ε-caprolactone) is a suitable polymeric material for forming an extended release matrix formulation which can provide a wide variety of release profiles when used in the form of melt formed multi particulates. The melt forming according to the invention can be accomplished by several methods, including extrusion, casting and injection molding. The multi particulates have preferably a diameter in the range of about 0.1 to about 3 mm.
[0074] Without wanting to be bound to any theory, it has also been found that poly(ε-caprolactone), due to its specific polymer characteristics, imparts a milling and/or grinding resistance to the extended release formulation in that the multi particles comprising poly(ε-caprolactone) do not form during milling and/or grinding smaller individual particles but in case of milling tend to fuse/melt together forming a lumpy mass and in case of grinding might deform. This is shown by Figures 14-2 and 14-3. It is believed that the release of the active agent does therefore not substantially change upon milling or grinding. In some cases the release is even slowed down. Thereby the extended release dosage form comprising said multi particulates is rendered less attractive for abuse. [0075] According to certain embodiments of the invention at least one poly(ε- caprolactone) with an approximate number average molecular weight of at least about 6,000 is used. According to certain embodiments of the invention the at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least about 10,000. According to certain embodiments of the invention the at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least about 20,000. According to certain embodiments of the invention the at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least about 25,000. According to certain embodiments of the invention the at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least about 37,000. According to certain embodiments of the invention the at least one poly(ε-caprolactone) has an approximate number average molecular weight of about 42,500. According to certain embodiments of the invention the at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least about 80,000. According to further certain embodiments of the invention, the at least one poly(ε-caprolactone) has an approximate number average molecular weight of between about 6,000 to about 80,000, or between about 10,000 and about 80,000, or between about 20,000 and about 80,000, or between about 25,000 and about 80,000or between about 37,000 and about 80,000, or between about 42,500 and about 80,000.
[0076] According to certain embodiments of the invention the extended release matrix formulation comprises at least two poly(ε-caprolactone) with an approximate number average molecular weight of between about 6,000 and about 25,000 and between about 37,000 and about 80,000, or between about 10,000 and about 25,000 and between about 37,000 and about 80,000, or between about 10,000 and about 25,000 and between about 42,500 and about 80,000. [0077] According to certain embodiments of the invention in the extended release matrix formulation the overall content of poly(ε-caprolactone) is at least about 50 weight-%, or at least about 60 weight-%, or at least about 70 weight-%, or at least about 80 weight-%, or at least about 90 weight-%, or between about 50 and about 90 weight-%, or between about 60 and about 90 weight-%, or between about 70 and about 90 weight-%, or between about 80 and about 90 weight-% of the extended release matrix formulation.
[0078] According to certain embodiments of the invention the extended release matrix formulation comprises least one poly(ε-caprolactone) with an approximate number average molecular weight of between about 37,000 and about 80,000 which is present at an amount of between about 50 and about 90 weight-% of the extended release matrix formulation.
[0079] According to certain embodiments of the invention the extended release matrix formulation comprises further at least one polyethylene glycol, which may be present at an amount of between about 1 and about 20 or about 1 and about 15 weight-%.
[0080] According to certain embodiments of the invention the extended release matrix formulation comprises further at least one high molecular weight polyethylene oxide with an approximate molecular weight of between about 1,000,000 and about 10,00O5OOO, based on rheological measurements. It is the finding of the inventors that the combination of poly(ε-caprolactone) and high molecular polyethylene oxide provide a resistance to milling and/or grinding in combination with a resistance to alcohol extraction thereby rendering the dosage form less attractive for illicit use and rendering the dosage form safer when used in combination with alcohol. The high molecular weight polyethylene oxide may be present at an amount of between about 5 and about 35 weight-%.
[0081] According to certain such embodiments of the invention the high molecular weight polyethylene oxide used has been screened through a screen with a size of 15/100 of the average diameter of the resulting melt formed multi particulate extended release formulation. According to certain embodiments the high molecular weight polyethylene oxide used has been screened with a 100 US mesh screen.
[0082] According to certain embodiments of the invention the extended release matrix formulation further comprises at least one poloxamer. The extended release matrix formulations may comprise further any other ingredients/excipients as conventional in the art.
[0083] According to certain embodiments of the invention the active agent is an opioid analgesic, in particular selected from the group of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, noφipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing. According to certain preferred embodiments of the invention the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
[0084] According to certain embodiments of the invention the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride or in particular comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 50 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg of oxycodone hydrochloride. According to certain such embodiments the oxycodone hydrochloride has a 14-hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm, or even less than 1 ppm.
[0085] According to certain embodiments of the invention the opioid analgesic is oxymorphone hydrochloride and the dosage form comprises from about 1 mg to about 500 mg of oxymorphone hydrochloride, in particular 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 50mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg of oxymorphone hydrochloride.
[0086] According to certain embodiments of the invention the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from about 1 mg to about 100 mg of hydromorphone hydrochloride, in particular 2 mg, 4 mg, 5 mg, 8 mg, 12 mg, 15 mg, 16 mg, 24 mg, 25 mg, 32 mg, 48 mg 50 mg, 64 mg or 75 mg of hydromorphone hydrochloride. [0087] According to certain embodiments of the invention the dosage form contains active in immediate release form, wherein the same or different active agents are in extended release and in immediate release form.
[0088] According to certain embodiments of the invention the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C, between about 12.5 % and about 55 % (by wt) active agent released after 1 hour, between about 25 % and about 65 % (by wt) active agent released after 2 hours, between about 45 % and about 85 % (by wt) active agent released after 4 hours and between about 55 % and about 95 % (by wt) active agent released after 6 hours.
[0089] According to certain embodiments of the invention the dosage form provides release rates of the active agent in- vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C between about 10 % and about 30% (by wt) active agent released after 2 hour, about 40 % and about 75 % (by wt) active agent released after 8 hours and no less than about 80%(by wt) active agent released after 22 hours.
[0090] According to certain embodiments of the invention the dosage form provides an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points or no more than about 10 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol. [0091] According to certain embodiments of the invention the dosage form provides after milling an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that increases no more than about 20 % points or no more than 10 % points or even decreases when compared to the corresponding in- vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without milling.
[0092] According to certain embodiments of the invention the dosage form provides after grinding an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that increases no more than about 20 % points or more than about 10 % points or even decreases when compared to the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without grinding.
[0093] According to certain embodiments of the invention the dosage form after milling provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points or no more than 10 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without ethanol at 37° C without milling. [0094] According to certain embodiments of the invention the dosage form after grinding provides an in- vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid, comprising 40% ethanol, at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points or no more than 10 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without ethanol at 37° C without grinding.
[0095] According to certain such embodiments of the invention as described in the paragraphs [0086] to [0092] above the active agent is oxycodone hydrochloride, hydromorphone hydrochloride or oxymorphone hydrochloride.
[0096] According to a certain aspect of the invention the dosage forms as described herein are used in a method of treating pain in a patient in need thereof, wherein the dosage form comprises an opioid analgesic and the use of such a dosage form for the manufacture of a medicament for the treatment of pain.
[0097] According to a certain aspect of the invention poly(ε-caprolactone) is used as matrix forming material in the manufacture of a solid extended release oral dosage form comprising an active agent selected from opioids for imparting to the solid extended release oral dosage form resistance to milling and/or grinding.
[0098] According to a certain aspect of the invention a process of preparing a solid oral extended release pharmaceutical dosage form is provided comprising the steps of:
- Melting and blending the poly(ε-caprolactone)and possible further ingredients except the active agent on a Thermodyne Hot Plate (temperature range about 90° - about 16O0C) for optionally approximately 3 minutes to obtain a mixture;
- Adding the active agent to the mixture on the Thermodyne Hot Plate (temperature range about 90° - about 1600C) until the mixture appeared homogeneous to obtain a blend;
Casting the molten blend by pressing between two stainless steel plates to a thickness of optionally approximately 2 millimeters and cooling to room temperature to obtain a sheet; and
Pelletizing the sheet by cutting into pellets of optionally approximately 2 mm in length and width.
According to a certain aspect of the invention a process of preparing a solid oral extended release pharmaceutical dosage form is provided comprising the steps of:
Screening active agent, poly(ε-caprolactone) and optionally other ingredients through a # 20 US mesh screen;
Blending the screened materials for optionally 10 minutes at ambient temperature;
Extruding the screened and blended materials in a twin screw extruder fitted with a die and set on counter-rotation with zone (barrel) temperatures ranged from about 18°C to about 110°C to obtain strands with a
Leistritz - ZSE 27 Twin Screw Extruder (Counter-Rotation)
Neslab Model CFT-150 Chiller
Accurate Powder Feeder
Dorner 8-foot Conveyor Grablab Electronic Timer
- Cooling the strands to ambient temperature;
- Pelletizing the cooled strands into pellets. In such a process the polyethylene oxide may be screened through a # 100 US mesh screen
[0099] According to a further aspect of the invention the solid oral extended release pharmaceutical dosage form is obtainable by a process as described above.
EXAMPLES
[00100] The present invention will now be more fully described with reference to the accompanying examples. It should be understood, however, that the following description is illustrative only and should not be taken in any way as a restriction of the invention.
EXAMPLE 1
The composition of the poly(ε-caprolactone) multiparticulates is summarized in Table 1 below.
Table 1
Figure imgf000030_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle.
2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 1600C) for approximately 3 minutes.
3. Melting and Blending: The Naltrexone HCl was slowly added to the PCL/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 3 minutes.
4. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
5. Cooling: The drug/polymer blend was cooled at room temperature. 6. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid with 0.1% Sodium Lauryl Sulfate or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 230 nm). Peristaltic pump (flow rate approx
5ml/min).
5. Equipment Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 1 and Table Ia.
Table Ia
Figure imgf000032_0001
Milling Procedure
Equipment: IKA Al 1 Basic Impact Mill Number of doses: 2 Duration of Milling: 15 seconds Milling Chamber: Stainless steel Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s
Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W
Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle
Number of doses: 2
Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were difficult to grind and fused/melted during milling.
EXAMPLE 2
The composition of the poly(ε-caprolactone) multiparticulates is summarized in Table 2 below.
Table 2
Figure imgf000034_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle.
2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 1600C) for approximately 3 minutes.
3. Melting and Blending: The polyethylene glycol (PEG 3350) was melted and mixed with the PCL/BHT mixture on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 3 minutes.
4. Weighing: The resulting polymer blend was weighed to determine the amount of PEG incorporated with Mettler, Sartorious balances.
5. Melting and Blending: The polymer blend was melted (temperature range 90° - 16O0C). The Naltrexone HCl was slowly added to the molten polymer blend and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 3 minutes. 6. Casting: The molten drag/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
7. Cooling: The drug/polymer blend was cooled at room temperature.
8. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid with 0.1% Sodium Lauryl Sulfate or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 230 run). Peristaltic pump (flow rate approx 5 ml/min).
5. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator Branson 8510 Sonicator The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 2 and Table 2a.
Table 2a
Figure imgf000036_0001
Milling Procedure
Equipment: IKA All Basic Impact Mill
Number of doses: 2 Duration of Milling: 15 seconds
Milling Chamber: Stainless steel
Chamber Volume: 80 ml
Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute
Circumferential Speed, idle: 76 m/s
Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W Motor rating output: 100 W Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle
Number of doses: 2
Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were difficult to grind but did not fuse/melt during milling.
EXAMPLE 3
The composition of the poly(ε-caprolactone) multi particulates is summarized in Table 3 below.
Table 3
Figure imgf000037_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle. 2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 1600C) for approximately 3 minutes.
3. Melting and Blending: The polyethylene oxide (PEO301) was slowly added to the beaker containing the melted PCL/BHT and mixed on a Thermodyne
Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous.
4. Melting and Blending: The Naltrexone HCl was slowly added to the PCL/PEO/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until the mixture appeared homogeneous.
5. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
6. Cooling: The drug/polymer blend was cooled at room temperature.
7. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid with 0.1% Sodium Lauryl Sulfate or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow 5. through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 6. Equipment Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 3 and Table 3 a.
Table 3a
Figure imgf000039_0001
Milling Procedure
Equipment: IKA All Basic Impact Mill Number of doses: 2 Duration of Milling: 15 seconds Milling Chamber: Stainless steel Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s
Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W
Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle
Number of doses: 2
Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were difficult to grind and fused/melted during milling.
EXAMPLE 4
The composition of the poly(ε-caprolactone) multiparticulates is summarized in Table 4 below.
Table 4
Figure imgf000041_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle.
2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 5 minutes.
3. Melting and Blending: The polyethylene oxide (PEO301) was slowly added to the beaker containing the melted PCL/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous.
4. Melting and Blending: The Naltrexone HCl was slowly added to the PCL/PEO/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until the mixture appeared homogeneous.
5. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters. 6. Cooling: The drag/polymer blend was cooled at room temperature.
7. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
2. Sampling time - every minute up to 720 minutes.
3. Media - 900 ml Simulated Gastric Fluid, Simulated Gastric Fluid with 0.1% Sodium Lauryl Sulfate or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method — UV Analysis, UV/Vis Spectrophotometer setup with flow
5. through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 6. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 4 and Table 4a. Table 4a
Figure imgf000043_0001
Milling Procedure Equipment: IKA Al 1 Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds
Milling Chamber: Stainless steel
Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571
Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute
Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W
Motor rating output: 100 W Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2 Duration of grinding: 20 rotations
The polyCε-caprolactone) pellets were difficult to grind but did not fuse/melt during milling.
EXAMPLE 5
The composition of this poly(ε-caprolactone) multiparticulate formulation is summarized in Table 5.
Table 5
Figure imgf000044_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle. 2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 5 minutes.
3. Melting and Blending: The poloxamer (Lutrol 68) was slowly added to the beaker containing the melted PCL/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous.
4. Melting and Blending: The Naltrexone HCl was slowly added to the PCL/Poloxamer/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until the mixture appeared homogeneous. 5. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
6. Cooling: The drug/polymer blend was cooled at room temperature.
7. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 370C.
2. Sampling time - every minute up to 1440 minutes. 3. Media - 900 ml Simulated Gastric Fluid or 900 ml Simulated Gastric Fluid with 40% ethanol. 4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min).
5. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 5 and Table 5 a.
Table 5a
Figure imgf000046_0001
Milling Procedure
Equipment: IKA Al 1 Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds Milling Chamber: Stainless steel
Chamber Volume: 80 ml
Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571
Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute
Circumferential Speed, idle: 76 m/s
Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W
Motor rating output: 100 W
Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle
Number of doses: 2
Duration of grinding: 20 rotations
The dissolution results for the milled poly(ε-caprolactone) multiparticules are summarized in Figure 5a and Table 5b.
The poly(ε-caprolactone) pellets were tough. The pellets did not fuse/melt during milling. Table 5b
Figure imgf000048_0001
EXAMPLE 6
The composition of this poly(ε-caprolactone) multiparticulate formulation is summarized in Table 6.
Table 6
Figure imgf000048_0002
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle. 2. Melting and Blending: The low moleculare weight poly(ε-caprolactone)
(PCL), high moleculare weight polycaprolactne (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 5 minutes.
3. Melting and Blending: The polyethylene oxide (PEO301) was slowly added to the beaker containing the melted PCL/BHT and mixed on a Thermodyne
Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous.
4. Melting and Blending: The Naltrexone HCl was slowly added to the PCL/PEO/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until the mixture appeared homogeneous.
5. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
6. Cooling: The drug/polymer blend was cooled at room temperature.
7. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling time — every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid, Simulated Gastric Fluid with 0.1% Sodium Lauryl Sulfate or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with Flow through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 5. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 6 and Table 6a.
Table 6a
Figure imgf000050_0001
Milling Procedure
Equipment: IKA Al 1 Basic Impact Mill Number of doses: 2 Duration of Milling: 15 seconds Milling Chamber: Stainless steel Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W
Grinding Procedure Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2 Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were tough and difficult to grind. During milling the discrete matrix particles formed a single fused mass.
EXAMPLE 7
The composition of this poly(ε-caprolactone) multiparticulate formulation is summarized in Table 7. Table 7
Figure imgf000052_0001
The following processing steps were used to manufacturing the poly(ε-caprolactone) multiparticulates.
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle.
2. Melting and Blending: The poly(ε-caprolactone) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 3 minutes.
3. Melting and Blending: The Naltrexone HCl was slowly added to the polymer mixture and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until the blend appeared homogeneous.
4. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 3.
5. Cooling: The drug/polymer blend was cooled at room temperature.
6. Pelletizing: The drug/polymer sheet was cut into pellets approximately 3 mm in length and width. Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpni at 370C.
2. Sampling time - every minute up to 1440 minutes. 3. Media - 900 ml Simulated Gastric Fluid (SGF), or Simulated Gastric Fluid with 40% ethanol (EtOH).
4. Analytical Method — UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 5. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell Changer and Dissolution Manifold with tubing/connectors) Gilson Minipuls3 Peristaltic Pump Hellma 10 mm Quarts Flow Cells Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240 Van KeI VK 7010 Dissolution Bath (Fitted with Baskets) Van KeI VK 750D Heater/Circulator Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 7 and Table 7a.
Table 7a
Figure imgf000054_0001
Milling Procedure Equipment: IKA Al 1 Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds
Milling Chamber: Stainless steel
Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571
Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute
Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W
Motor rating output: 100 W
The poly(ε-caprolactone) pellets were tough and fused/melted during milling. EXAMPLE 8
The composition of this poly(ε-caprolactone) multiparticulate formulation is summarized in Table 8.
Table 8
Figure imgf000055_0001
The following processing steps were used to manufacturing the poly(ε-caprolactone) multiparticulates .
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle.
2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range
90° - 1600C) for approximately 3 minutes.
3. Melting and Blending: The Naltrexone HCl was slowly added to the polymer mixture and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until the blend appeared homogeneous. 4. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters. 5. Cooling: The drug/polymer blend was cooled at room temperature.
6. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
2. Sampling time — every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid (SGF) with 0.5% Sodium Lauryl Sulfate (SLS)5 Simulated Gastric Fluid (SGF) with 0.1% Sodium Lauryl
Sulfate (SLS) or Simulated Gastric Fluid with 40% ethanol (EtOH).
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 5. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticulates are summarized in Figure 8 and Table 8a. Table 8a
Figure imgf000057_0001
Milling Procedure
Equipment: IKlA Al 1 Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds
Milling Chamber: Stainless steel Chamber Volume: 80 ml
Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571
Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s
Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W
Motor rating output: 100 W
Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2
Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were difficult to grind and fused/melted during milling.
EXAMPLE 9
The composition of this poly(ε-caprolactone) multiparticulate formulation is summarized in Table 9.
Table 9
Figure imgf000058_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle. 2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 5 minutes.
3. Melting and Blending: The polyethylene oxide (PEO301) was slowly added to the beaker containing the melted PCL/BHT and mixed on a Thermodyne
Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous.
4. Melting and Blending: The Naltrexone HCl was slowly added to the PCL/PEO/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 1600C) until the mixture appeared homogeneous.
5. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
6. Cooling: The drug/polymer blend was cooled at room temperature.
7. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow 5. through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 6. Equipment Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 9 and Table 9a.
Table 9a
Figure imgf000060_0001
Milling Procedure
Equipment: IKA Al 1 Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds
Milling Chamber: Stainless steel
Chamber Volume: 80 ml
Blade: Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W
Grinding Procedure Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2 Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were difficult to grind and fused/melted during milling.
EXAMPLE 10
The composition of this poly(ε-caprolactone) multiparticulate formulation is summarized in Table 10.
Table 10
Figure imgf000062_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle.
2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 5 minutes.
3. Melting and Blending: The polyethylene Glycol (PEG 3350) was slowly added to the beaker containing the melted PCL/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous. 4. Melting and Blending: The polyethylene oxide (PEO301) was slowly added to the beaker containing the melted PCL/PEG/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous.
5. Melting and Blending: The Naltrexone HCl was slowly added to the PCL/PEO/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until the mixture appeared homogeneous.
6. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
7. Cooling: The drug/polymer blend was cooled at room temperature.
8. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 370C. 2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid, Simulated Gastric Fluid with 0.1% Sodium Lauryl Sulfate or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow 5. through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 6. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors) Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240 Van KeI VK 7010 Dissolution Bath (Fitted with Baskets) Van KeI VK 750D Heater/Circulator Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 10 and Table 10a.
Table 10a
Figure imgf000064_0001
Milling Procedure
Equipment: IKA Al 1 Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds Milling Chamber: Stainless steel
Chamber Volume: 80 ml
Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571
Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute
Circumferential Speed, idle: 76 m/s
Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W Motor rating output: 100 W
Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2
Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were difficult to grind and fused/melted during milling. The dissolution results for milled samples are summarized in Figure 10a and Table 10b.
Table 10b
Figure imgf000065_0001
EXAMPLE 11
The composition of this poly(ε-caprolactone) multiparticulate formulation is summarized in Table 11. Table 11
Figure imgf000066_0001
The processing steps for manufacturing the poly(ε-caprolactone) multiparticulates are as follows:
1. Milling: The butylated hydroxytoluene (BHT) was milled with a mortar and pestle.
2. Melting and Blending: The poly(ε-caprolactone) (PCL) and milled BHT were melted and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) for approximately 5 minutes.
3. Melting and Blending: The polyethylene oxide (PEO301) was slowly added to the beaker containing the melted PCL/BHT and mixed on a Thermodyne Thermodyne Hot Plate (temperature range 90° - 16O0C) until mixture appeared homogeneous. 4. Melting and Blending: The Naltrexone HCl was slowly added to the
PCL/PEO/BHT and mixed on a Thermodyne Hot Plate (temperature range 90° - 16O0C) until the mixture appeared homogeneous. 5. Casting: The molten drug/polymer blend was pressed between two stainless steel plates to a thickness of approximately 2 millimeters.
6. Cooling: The drug/polymer blend was cooled at room temperature.
7. Pelletizing: The drug/polymer sheet was cut into pellets approximately 2 mm in length and width.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 370C. 2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid or 900 ml Simulated Gastric Fluid with 40% ethanol.
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow 5. through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min). 6. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors) Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets) Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 11 and Table 11a.
Table 11a
Figure imgf000068_0001
Milling Procedure
Equipment: IKlA Al 1 Basic Impact Mill
Number of doses: 2 Duration of Milling: 15 seconds
Milling Chamber: Stainless steel
Chamber Volume: 80 ml
Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute
Circumferential Speed, idle: 76 m/s
Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W Motor rating output: 100 W The poly(ε-caprolactone) pellets were waxy and brittle. They did not fuse/melt during milling.
EXAMPLE 12
The composition of the poly(ε-caprolactone) melt extruded multiparticulates is summarized in Table 12 below.
Table 12
Figure imgf000069_0001
* Weigh is not corrected for water or impurities
The processing conditions at the time of sampling are summarized below.
Extruder: Leistritz ZSE 27 Screw Configuration: Counter-rotation
Figure imgf000070_0001
Torque (%): 97 Melt Pressure (psi): 1930 Feed rate (g/min.): 20 Screw speed (rpm): 66 Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
Equipment Leistritz - ZSE 27 Twin Screw Extruder (Counter-Rotation) Neslab Model CFT-150 Chiller Accurate Powder Feeder Dorner 8-foot Conveyor Grablab Electronic Timer The processing steps for manufacturing Poly(ε-caprolactone) melt extruded multiparticulates are as follows:
1. Screening: Naltrexone HCl, Poly(ε-caprolactone), Polyethylene oxide and
BHT were screened through a # 20 US mesh screen. 2. Blending: The materials screened in Step 1 were loaded into an 8 qt. V- blender QA Poly(ε-caprolactone), Naltrexone HCl5 Polyethylene oxide, BHT and 1A Poly(ε-caprolactone)) and blended for 10 minutes at ambient temperature.
3. Extrusion: Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into approximately 1 mm strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 18°C to 88°C.
4. Cooling: The strands were cooled on a conveyor at ambient temperature.
5. Pelletizing: The cooled strands were cut into pellets approximately 1 mm in length.
Dissolution Method
The following method was used to test the dissolution of the poly(ε-caprolactone) multiparticulates .
1. Apparatus- USP Type I (Baskets), 100 rpm at 370C.
2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid (SGF) or Simulated Gastric Fluid with 40% ethanol (EtOH).
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min).
5. Equipment Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator Branson 8510 Sonicator
The dissolution results for the poly(ε-caprolactone) multiparticules are summarized in Figure 12 and Table 12a.
Table 12a
Figure imgf000072_0001
Milling Procedure Equipment: IKA All Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds
Milling Chamber: Stainless steel
Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034
Rotor Shaft: Stainless steel 1.4571
Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute
Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s
Motor rating input: 160 W
Motor rating output: 100 W Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2 Duration of grinding: 20 rotations
The poly(ε-caprolactone) pellets were difficult to crush with a mortar and pestle. They fused/melted during milling but incomplete after 15 seconds.
The dissolution results for the ground (Figure 12a and Table 12b) and milled (Figure 12b and Table 12c) poly(ε-caprolactone) pellets are summarized below.
Table 12b
Figure imgf000073_0001
Table 12c
Figure imgf000073_0002
EXAMPLE 13
The composition of the Poly(ε-caprolactone) melt extruded multiparticulates is summarized in Table 13 below.
Table 13
Figure imgf000074_0001
* Weigh is not corrected for water or impurities
The processing conditions at the time of sampling are summarized below. Extruder: Leistritz ZSE 27
Screw Configuration: Counter-rotation
Sample 1 mm Strands
Figure imgf000074_0002
Torque (%): 53
Melt Pressure (psi): 890
Feed rate (g/min.): 11
Screw speed (rpm): 20
Melt Temp. (°C): 94
Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
Sample 1.5 mm Strands
Figure imgf000075_0001
Torque (%): 55
Melt Pressure (psi): 870
Feed rate (g/min.): 11
Screw speed (rpm): 20
Melt Temp. (°C): 93
Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
Sample 2 mm Strands
Heating Zone 1 2 3 4 5 6 7 8 9 10 11 12
Temperature 48 60 87 95 97 10 11 10 93 95 80 81 (°C) 3 0 3
Torque (%): 62 Melt Pressure (psi) 370 Feed rate (g/min.): 22 Screw speed (rpm): 50 Melt Temp. (0C): 89
Die Plate Hole diameter (mm): 3.0 (10-hole die plate)
Equipmet
Leistritz - ZSE 27 Twin Screw Extruder (Counter-Rotation) Neslab Model CFT- 150 Chiller Accurate Powder Feeder Dorner 8-foot Conveyor Grablab Electronic Timer
The processing steps for manufacturing Poly(ε-caprolactone) melt extruded multiparticulates are as follows:
1. Screening: Naltrexone HCl, Poly(ε-caprolactone), Polyethylene Glycol and BHT were screened through a # 20 US mesh screen. Polyethylene oxide screened through a #100 US mesh screen.
2. Blending: The materials screened in Step 1 were loaded into an 8 qt. V-blender QA Poly(ε-caprolactone), Naltrexone HCl, Polyethylene oxide, polyethylene glycol, BHT and 1A Poly(ε-caprolactone)) and blended for 10 minutes at ambient temperature.
3. Extrusion: Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 18°C to 110°C.
4. Cooling: The strands were cooled on a conveyor at ambient temperature. 5. Pelletizing: The cooled strands were cut into pellets approximately 1.0 mm, 1.5 mm and 2.0 mm in length for Sample #3, Sample #4 and Sample #1, respectively.
Dissolution Method
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C.
2. Sampling time — every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid (SGF) or Simulated Gastric Fluid with 40% ethanol (EtOH).
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 230 nm). Peristaltic pump (flow rate approx 5 ml/min).
5. Equipment Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump
Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator
Branson 8510 Sonicator
Milling Procedure
Equipment: IKA Al 1 Basic Impact Mill
Number of doses: 2
Duration of Milling: 15 seconds Milling Chamber: Stainless steel Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute
Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W
Grinding Procedure
Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2 Duration of grinding: 20 rotations
Results
The dissolution results for the 1.0 mm (Table 13-la, Figure 13-1), 1.5 mm (Table 13- 2a, Figure 13-2) and 2.0 mm (Table 13-3a, Figure 13-3) poly(ε-caprolactone) pellets are summarized below.
The 1.0 mm, 1.5 mm and 2.0 mm poly(ε-caprolactone) pellets were difficult to grind with a mortar and pestle. All pellet samples fused/melted during milling. Dissolution results for the milled and ground pellets are summarized for the 1.0 mm (Figure 13-1 and Table 13-lb and c), 1.5 mm (Figure 13-2 and Table 13-2b and c) and 2.0 mm (Figure 13-3 and Table 13-3b and c) below. Table 13-la
Figure imgf000079_0001
Table 13-lb
Figure imgf000079_0002
Table 13-lc
Figure imgf000079_0003
Table 13-2a
Figure imgf000079_0004
Table 13-2b
Figure imgf000080_0001
Table 13-2c
Figure imgf000080_0002
Table 13-3a
Figure imgf000080_0003
Table 13-3b
Figure imgf000080_0004
Table 13-3c
Figure imgf000081_0001
Futher Equipment used in the Examples Mettler, Sartorious balances Starrett Micrometers Fluka Digital Thermometer Carver Model 4332 Press
[00101] The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.
[00102] A number of references have been cited, the entire disclosures of which are incorporated herein by reference in their entireties for all purposes.
EXAMPLE 14
The composition of the Poly(ε-caρrolactone) melt extruded multiparticulates/pellets is summarized in Table 14 below. Table 14
Figure imgf000082_0001
* Weigh is not corrected for water or impurities
The processing conditions at the time of sampling are summarized below. Extruder: Leistritz ZSE 27
Screw Configuration: Counter-rotation
Figure imgf000082_0002
Torque (%): 57-67
Melt Pressure (psi): 230-270
Feed rate (g/min.): 20-22
Screw speed (rpm): 20
Melt Temp. (0C): 93-96
Die Plate Hole diameter (mm): 3.0 (10-hole die plate)
Strand diameter: approximately 1.5 mm Equipment
Leistritz ZSE 27 Twin Screw Extruder (Counter-Rotation) Neslab Model CFT-150 Chiller Accurate Powder Feeder Dorner 8-foot Conveyor Grablab Electronic Timer Lasermike
Randcastle Pelletizer
The processing steps for manufacturing Poly(ε-caprolactone) melt extruded multiparticulates/pellets are as follows:
1. Screening Oxycodone HCl, Poly(ε-caprolactone) and BHT were screened through a # 20 US mesh screen. Polyethylene Glycol was screened through a
#60 US mesh screen. Polyethylene oxide was screened through a #100 US mesh screen.
2. Blending: The materials screened in Step 1 were loaded into a 16 qt. V-blender (/4 Poly(ε-caprolactone), Oxycodone HCl, Polyethylene oxide, polyethylene glycol, BHT and 1A Poly(ε-caprolactone)) and blended for 10 minutes at ambient temperature.
3. Extrusion: Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 14°C to 90°C. 4. Cooling: The strands were cooled on a conveyor at ambient temperature.
5. Pelletizing: The cooled strands were cut into pellets approximately 1.5 mm in length. Dissolution Method I
1. Apparatus- USP Type I (Baskets), 100 rpm at 370C. 2. Sampling time - every minute up to 1440 minutes.
3. Media - 900 ml Simulated Gastric Fluid or Simulated Gastric Fluid with 40% ethanol (EtOH).
4. Analytical Method - UV Analysis, UV/Vis Spectrophotometer setup with flow through cells (wavelength 240 nm). Peristaltic pump (flow rate approx 5 ml/min).
5. Equipment
Perkin-Elmer Lambda 20 UV/Vis Spectrophotometer (8 - Position Cell
Changer and Dissolution Manifold with tubing/connectors)
Gilson Minipuls3 Peristaltic Pump Hellma 10 mm Quarts Flow Cells
Perkin-Elmer UV WinLab Software/Microsoft Window 95 and Excel
Hewlett-Packard Pavilion Computer Model 8240
Van KeI VK 7010 Dissolution Bath (Fitted with Baskets)
Van KeI VK 750D Heater/Circulator Branson 8510 Sonicator
Milling Procedure
Equipment: IKA Al 1 Basic Impact Mill Number of doses: Approximately 2 Duration of Milling: 15 seconds Milling Chamber: Stainless steel Chamber Volume: 80 ml Blade: Stainless steel beater 1.4034 Rotor Shaft: Stainless steel 1.4571 Motor Speed, idle: 28000 revolutions/minute Motor Speed, under load: 25000 revolutions/minute Circumferential Speed, idle: 76 m/s Circumferential Speed, under load: 53 m/s Motor rating input: 160 W Motor rating output: 100 W
Milling Procedure (Coffee Mill) Equipment: Cuisinart Model DCG-12BC (120V, 60Hz, 12W)
Number of units: Approximately 2 units for pellets, 1 unit for tablet (comparison) Duration of Milling: 60 seconds
Grinding Procedure Equipment: 8 oz Glass Mortar with Pestle Number of doses: 2 Duration of grinding: 20 rotations
The dissolution results are summarized below in table 14- Ia to c.
The poly(ε-caprolactone) pellets were difficult to grind with a mortar and pestle. All pellet samples fused/melted during milling. Dissolution results for the intact (Table 14- Ia), milled (Table 14- Ib) and ground (Table 14- Ic) pellets are summarized below. Figure 14-2 depicts the a) intact, b) milled and c) ground pellets. Figure 14-3 depicts the a) the example pellets milled in a coffee mill and b) a comparison tablet without poly(ε-caprolactone) milled in a coffee mill. The composition and preparation of the comparison tablet without poly(ε-caprolactone) can be found in WO 2008/023261 Example 14.5. Table 14-la
Figure imgf000086_0001
Table 14-lb
Figure imgf000086_0002
Table 14-lc
Figure imgf000086_0003
Stability Testing The 1.5 mm pellets were placed on stability at 25°C/60% relative humidity (RH) and 40°C/75% RH in induction sealed high density polyethylene bottles (HDPE) with and without desiccant.
Assay Method
The following method was used to assay the multiparticulates described in the example.
1. Extraction Solvent: 1 :2 mixture acetonitrile and simulated gastric fluid without enzymes (SGF).
2. Analytical Method: Reversed-phase high performance liquid chromatography (HPLC) on a Waters Atlantis dC18 3.0 x 250 mm, 5 μm column maintained at 60°C using a mobile phase consisting of acetonitrile and potassium phosphate monobasic buffer at pH 3.0 with UV detection at 280 nm. Flow rate 1.0 ml/minute.
3. Equipment
Waters Alliance 2695 HPLC system with 2487 UV- Visible absorbance detector Stir Plate
Degradation Products Method
The following method was used to determine the degradation products of oxycodone HCl in the multiparticulates described in the example. Oxycodone N-oxide is the only known degradation product included in the % total degradation products. Noroxymorphone, oxymorphone, 10-hydroxyoxycodone, 6-α-oxycodol, 7,8-hydro-8, 14-dihydroxycodeinone, and hydrocodone which are known process impurities can be identified with this method but are not included in the calculation of % total degradation products. 1. Extraction Solvent: 1 :2 mixture acetonitrile and simulated gastric fluid without enzymes (SGF).
2. Analytical Method: Reversed-phase high performance liquid chromatography (HPLC) on a YMC-Pack ODS-AQ 4.6 x 250 mm, 3 μm column maintained at 60°C using a mobile phase consisting of acetonitrile and potassium phosphate monobasic buffer at pH 3.0 with UV detection at 206 nm. Flow rate l.O ml/min.
3. Equipment Waters Alliance 2695 HPLC system with 2487 UV-Visible absorbance detector
Waters Empower Software Stir Plate
Dissolution Method II
The following method was used to test the dissolution of the multiparticulate stability samples described in the example.
1. Apparatus- USP Type I (Baskets), 100 rpm at 37°C. 2. Sampling Time- Generally, 1 hour, 2 hrs., 4 hrs., 8hrs., 12 hrs., 18 hrs. and 24 hrs.
3. Media - 900 ml Simulated Gastric Fluid without enzyme (SGF).
4. Analytical Method - Reversed-phase high performance liquid chromatography (HPLC) on a Waters Atlantis dC18 3.0 x 250 mm, 5 μm column maintained at 60°C using a mobile phase consisting of acetonitrile and potassium phosphate monobasic buffer at pH 3.0 with UV detection at 230 nm. Flow rate 1.0 ml/minute. Equipment
Waters Alliance 2695 HPLC system with transfer module and 2487 UV- Visible absorbance detector Waters Empower Software Hanson SR8 Plus Dissolution Bath
The assay, impurities and dissolution (Method II) results are summarized in Tables 14-2 and 14-3 after one month at 25°C/60% RH and 40°C/75% RH with and without desiccant.
Table 14-2
Figure imgf000089_0001
< LOQ= Less Than Limit of Quantitation = 0 1% Table 14-3
Figure imgf000090_0001
Small Volume Extraction Testing
The extraction of oxycodone HCl from 1.5 mm pellets using absolute anhydrous ethanol was evaluated at room temperature.
Small Volume Extraction Method
1. Extraction Solvent: 30 ml Absolute Anhydrous Ethanol 2. Number of Units : Approximately 2
3. Shaking Time: 1 hour
4. Diluting Solvent: Absolute Anhydrous Ethanol
5. Analysis: UV/Visible Spectrophotometer (wavelength 240 nm) 6. Equipment
Agilent 8453 UV/Vis Spectrophotometer with ChemStation Software Hewlett-Packard Vectra Computer/Windows XP Hellma 10 mm Quartz Cell Burrell Model 75 Shaker
The results are summarized in Table 14-4. An average of 5.6 % oxycodone HCl was extracted.

Claims

1. A solid oral extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(ε-caprolactone), and at least one active agent.
2. The solid oral extended release pharmaceutical dosage form of claim 1, wherein the melt is formed by an extrusion method.
3. The solid oral extended release pharmaceutical dosage form of claim 1, wherein the melt is formed by a casting method.
4. The solid oral extended release pharmaceutical dosage form of claim 1, wherein the melt is formed by an injection molding method.
5. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 4, wherein at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least about 10,000.
6. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 4, wherein the at least one poly(ε-caprolactone) has an approximate number average molecular weight of at least about 37,000.
7. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 4, wherein the at least one poly(ε-caprolactone) has an approximate number average molecular weight of between about 10,000 to about 80,000.
8. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 4, wherein the at least one poly(ε-caprolactone) has an approximate number average molecular weight of between about 37,000 and about 80,000.
9. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 4, comprising at least a first poly(ε-caprolactone) with an approximate number average molecular weight of between about 10,000 and about 25,000 and a second poly(ε-caprolactone) with an approximate number average molecular weight of between about 37,000 and about 80,000.
10. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 9, wherein poly(ε-caprolactone) is present at an amount of at least about 50 weight-% of the extended release matrix formulation.
11. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 9, wherein poly(ε-caprolactone) is present at an amount of at least about 60 weight-% of the extended release matrix formulation.
12. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 9, wherein poly(ε-caprolactone)is present at an amount of between about 50 and about 90 weight-% of the extended release matrix formulation.
13. The solid oral extended release pharmaceutical dosage form according to according to any one of claims 1 to 4, wherein the least one poly(ε-caprolactone) has an approximate number average molecular weight of between about 37,000 and about 80,000 and is present at an amount of between about 50 and about 90 weight-% of the extended release matrix formulation.
14. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 13, wherein the multi particulates have a diameter in the range of about 0.1 to about 3 mm.
15. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 14, wherein the extended release matrix formulation further comprises at least one polyethylene glycol.
16. The solid oral extended release pharmaceutical dosage form according to claim 15, wherein the polyethylene glycol is present at an amount of between about 1 and about 20 weight-%
17. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 16, wherein the extended release matrix formulation further comprises at least one high molecular weight polyethylene oxide.
18. The solid oral extended release pharmaceutical dosage form according to claim 17, wherein high molecular weight polyethylene oxide has a molecular weight of between about 1,000,000 and about 10,000,000, based on rheological measurements.
19. The solid oral extended release pharmaceutical dosage form according to any one of claims 17 and 18, wherein high molecular weight polyethylene oxide is present at an amount of between about 5 and about 35 weight-%.
20. The solid oral extended release pharmaceutical dosage form according to any one of claims 17 to 19, wherein a high molecular weight polyethylene oxide is used which has been screened with a screen with a size of 1/10 or less of the average diameter of the resulting melt formed multi particulate extended release formulation.
21. The solid oral extended release pharmaceutical dosage form according to any one of claims 17 to 19, wherein a high molecular weight polyethylene oxide is used which has been screened with a 100 US mesh screen or a finer screen.
22. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 21, wherein the extended release matrix formulation further comprises at least one poloxamer.
23. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 22, wherein active agent is an opioid analgesic.
24. The solid oral extended release pharmaceutical dosage form according to claim 23, wherein the opioid analgesic is selected from the group of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiarnbutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmoφhine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts, hydrates and solvates thereof, and mixtures of any of the foregoing.
25. The solid oral extended release pharmaceutical dosage form of claim 24, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, and mixtures of any of the foregoing.
26. The solid oral extended release pharmaceutical dosage form of claim 25, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride.
27. The solid oral extended release pharmaceutical dosage form of claim 26, wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 50 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg of oxycodone hydrochloride.
28. The solid oral extended release pharmaceutical dosage form of claim 27, wherein the opioid analgesic is oxycodone hydrochloride having a 14- hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, less than about 5 ppm, or less than about 1 ppm.
29. The solid oral extended release pharmaceutical dosage form of claim 25, wherein the opioid analgesic is oxymorphone hydrochloride and the dosage form comprises from about 1 mg to about 500 mg of oxymorphone hydrochloride.
30. The solid oral extended release pharmaceutical dosage form of claim 29, wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 50 mg 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg of oxymorphone hydrochloride.
31. The solid oral extended release pharmaceutical dosage form of claim 25, wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from about 1 mg to about 100 mg of hydromorphone hydrochloride.
32. The solid oral extended release pharmaceutical dosage form of claim 31, wherein the dosage form comprises 2 mg, 4 mg, 5 mg, 8 mg, 12 mg, 15 mg, 16 mg, 24 mg, 25 mg, 32 mg, 48 mg, 50 mg, 64 mg or 75 mg of hydromorphone hydrochloride.
33. The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 32, which contains active in immediate release form.
34. The solid oral extended release pharmaceutical dosage form of claim 33, wherein the same or different active agents are in extended release and in immediate release forms.
35. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 34, wherein the dosage form provides release rates of the active agent in-vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 °C, between about 12.5 % and about 55 % (by wt) active agent released after 1 hour, between about 25 % and about 65 % (by wt) active agent released after 2 hours, between about 45 % and about 85 % (by wt) active agent released after 4 hours and between about 55 % and about 95 % (by wt) active agent released after 6 hours.
36. The solid oral extended release pharmaceutical dosage form of claim 35, wherein the active agent is oxycodone hydrochloride.
37. The solid oral extended release pharmaceutical dosage form of claim 35, wherein the active agent is hydromorphone hydrochloride.
38. The solid oral extended release pharmaceutical dosage form of claim 35, wherein the active agent is oxymorphone hydrochloride.
39. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 34, wherein the dosage form provides release rates of the active agent in-vitro when measured by the USP Basket Method at 100 rpm at 900 ml simulated gastric fluid at 37 0C between about 10 % and about 30% (by wt) active agent released after 2 hour, about 40 % and about 75 % (by wt) active agent released after 8 hours and no less than about 80%(by wt) active agent released after 22 hours.
40. The solid oral extended release pharmaceutical dosage form of claim 39, wherein the active agent is hydromorphone hydrochloride.
41. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 40, wherein the dosage form provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without ethanol.
42. The solid oral extended release pharmaceutical dosage form according to claim 41, wherein the percent amount of active agent released at 1 hour of dissolution deviates no more than about 10 % points.
43. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 42, wherein the dosage form provides after milling an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that increases no more than about 20 % points when compared to the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without milling.
44. The solid oral extended release pharmaceutical dosage form according to claim 43, wherein the percent amount of active agent released at 1 hour of dissolution increases no more than about 10 % points.
45. The solid oral extended release pharmaceutical dosage form according to claim 43, wherein the percent amount of active agent released at 1 hour of dissolution decreases when oral compared to the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without milling.
46. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 45, wherein the dosage form provides after grinding an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that increases no more than about 20 % points when compared to the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without grinding.
47. The solid oral extended release pharmaceutical dosage form according to claim 46, wherein the percent amount of active agent released at 1 hour of dissolution increases no more than about 10 % points.
48. The solid oral extended release pharmaceutical dosage form according to claim 46, wherein the percent amount of active agent released at 1 hour of dissolution decreases when compared to the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid at 37° C without grinding.
49. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 48, wherein the dosage form after milling provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid comprising 40% ethanol at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without ethanol at 37° C without milling.
50. The solid oral extended release pharmaceutical dosage form according to claim 49, wherein the percent amount of active agent released at 1 hour of dissolution deviates no more than about 10 % points.
51. The solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 50, wherein the dosage form after grinding provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid, comprising 40% ethanol, at 37° C, characterized by the percent amount of active agent released at 1 hour of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without ethanol at 37° C without grinding.
52. The solid oral extended release pharmaceutical dosage form according to claim 51, wherein the percent amount of active agent released at 1 hour of dissolution deviates no more than about 10 % points.
53. The solid oral extended release pharmaceutical dosage form according to any one of claims 41 to 52, wherein the active agent is oxycodone hydrochloride.
54. The solid oral extended release pharmaceutical dosage form according to any one of claims 41 to 52, wherein the active agent is hydromorphone hydrochloride.
55. The solid oral extended release pharmaceutical dosage form according to any one of claims 41 to 52, wherein the active agent is oxymorphone hydrochloride.
56. A solid oral extended release pharmaceutical dosage form which is resistant to milling and grinding.
57. The solid oral extended release pharmaceutical dosage form according to claim 56, wherein the dosage form is resistant to alcohol extraction.
58. A method of treatment wherein a solid oral extended release pharmaceutical dosage form according to any one of claims 1 to 57 is administered for treatment of pain to a patient in need thereof, wherein the dosage form comprises an opioid analgesic.
59. Use of a solid extended release pharmaceutical dosage form according to any one of claims 1 to 57 for the manufacture of a medicament comprising a solid oral extended release pharmaceutical dosage form for the treatment of pain, wherein the dosage form comprises an opioid analgesic.
60. Use of poly(ε-caprolactone) as matrix forming material in the manufacture of a solid oral extended release pharmaceutical dosage form comprising an active agent selected from opioids for imparting to the solid e oral extended release dosage form resistance to milling.
61. A process of preparing a solid oral extended release pharmaceutical dosage form comprising the steps of:
- Melting and blending the poly(ε-caprolactone) (PCL) and possible further ingredients except the active agent on a Thermodyne Hot Plate (temperature range 90° - 16O0C) to obtain a mixture;
- Adding the active agent to the mixture on the Thermodyne Hot Plate (temperature range about 90° - about 16O0C) until the mixture appeared homogeneous to obtain a blend;
- Placing the molten blend on a stainless steel plate and pressing with a second stainless steel plate and cooling to room temperature to obtain a sheet with a given thickness; and - Pelletizing the sheet by cutting into pellets.
62. The process of claim 61, wherein the thickness of the sheet is approximately 2 mm and the pellets have approximately 2 mm in length and width.
63. A process of preparing a solid oral extended release pharmaceutical dosage form comprising the steps of:
- Screening active agent, ρoly(ε-caprolactone) and optionally other ingredients through a # 20 US mesh screen; - Blending the screened materials at ambient temperature;
- Extruding the screened and blended materials in a twin screw extruder fitted with a die and set on counter-rotation with zone (barrel) temperatures ranged from about 18°C to about 110°C to obtain stands; - Cooling the strands to ambient temperature;
- palletizing the cooled strands into pellets.
64. The process of claim 63, wherein the solid oral extended release pharmaceutical dosage form comprises polyethylene oxide and the polyethylene oxide is screened through a # 100 US mesh screen or finer.
65. A solid oral extended release pharmaceutical dosage form obtainable by a process according to any one of claims 61 to 64.
PCT/IB2009/006917 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone) WO2010032128A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2737257A CA2737257C (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone)
KR1020117008610A KR101456741B1 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone)
JP2011527420A JP5539991B2 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage form comprising poly (ε-caprolactone)
US13/055,535 US20110165248A1 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone)
ES09786269.2T ES2586439T3 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly (E-caprolactone)
BRPI0913724A BRPI0913724B8 (en) 2008-09-18 2009-09-17 extended release dosage forms comprising naltrexone and poly (e-caprolactone) and their preparation
RU2011121010/15A RU2523896C2 (en) 2008-09-18 2009-09-17 Pharmaceutical drug forms, containing poly-(epsilon-caprolactone)
NZ592276A NZ592276A (en) 2008-09-18 2009-09-17 PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID
AU2009294308A AU2009294308B2 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone)
UAA201104686A UA101405C2 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone)
CN200980136742.4A CN102159193B (en) 2008-09-18 2009-09-17 Comprise the pharmaceutical dosage form of poly-(6-caprolactone)
EP09786269.2A EP2344136B1 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone)
MX2011002966A MX342643B (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone).
IL211314A IL211314A (en) 2008-09-18 2011-02-20 Pharmaceutical dosage forms comprising poly (epsilon-caprolactone)
ZA2011/01948A ZA201101948B (en) 2008-09-18 2011-03-15 Pharmaceutical dosage forms comprising poly(e-caprolactone)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9808908P 2008-09-18 2008-09-18
US61/098,089 2008-09-18
US22349709P 2009-07-07 2009-07-07
US61/223,497 2009-07-07

Publications (1)

Publication Number Publication Date
WO2010032128A1 true WO2010032128A1 (en) 2010-03-25

Family

ID=41435149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006917 WO2010032128A1 (en) 2008-09-18 2009-09-17 Pharmaceutical dosage forms comprising poly(e-caprolactone)

Country Status (16)

Country Link
US (1) US20110165248A1 (en)
EP (1) EP2344136B1 (en)
JP (1) JP5539991B2 (en)
KR (1) KR101456741B1 (en)
CN (1) CN102159193B (en)
AU (1) AU2009294308B2 (en)
BR (1) BRPI0913724B8 (en)
CA (1) CA2737257C (en)
CO (1) CO6361903A2 (en)
ES (1) ES2586439T3 (en)
IL (1) IL211314A (en)
MX (1) MX342643B (en)
NZ (2) NZ592276A (en)
RU (1) RU2523896C2 (en)
WO (1) WO2010032128A1 (en)
ZA (1) ZA201101948B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2013030267A1 (en) 2011-08-30 2013-03-07 Universiteit Gent Multi-layered release formulation
WO2013084059A1 (en) * 2011-12-09 2013-06-13 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly (epsilon- caprolactone) and polyethylene oxide
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8808745B2 (en) 2001-09-21 2014-08-19 Egalet Ltd. Morphine polymer release system
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9168228B2 (en) 2009-02-06 2015-10-27 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3181124A1 (en) 2015-12-16 2017-06-21 Universität Basel Abuse deterrent pharmaceutical dosage forms
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2010033195A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
MX356111B (en) 2012-04-18 2018-05-15 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions.
BR112015021002B8 (en) 2013-03-15 2023-03-28 Mallinckrodt Llc SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING AN ACTIVE PHARMACEUTICAL INGREDIENT
US11617712B2 (en) 2014-07-03 2023-04-04 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
CN107405304B (en) * 2015-02-04 2021-05-04 财团法人卫生研究院 Sorbitan polyester complexes for stabilizing water-in-oil emulsions and controlled release of biologically active substances
MX2021002459A (en) 2018-09-25 2021-04-29 SpecGx LLC Abuse deterrent immediate release capsule dosage forms.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US20050096388A1 (en) * 1996-05-24 2005-05-05 Angiotech International Ag Compositions and methods for treating or preventing diseases of body passageways
WO2006082099A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant delayed-release forms of administration

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2557459B1 (en) * 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique POLYCAPROLACTONE-BASED INERT MATRIX FOR ORAL ADMINISTRATION OF A MEDICAMENT, AND METHOD FOR PREPARING THE GALENIC FORM COMPRISING THE SAME
US5716565A (en) * 1993-09-27 1998-02-10 Alfred University Process for making ultra-fine stabilized zirconia particles
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2248908T7 (en) 1997-06-06 2014-11-24 Depomed, Inc. Dosage forms of drugs orally and gastric retention for continued release of highly soluble drugs
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
UA73092C2 (en) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Tablets with enteric coating and method for their manufacture
OA11728A (en) * 1998-12-16 2005-02-01 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.
EP2316440A1 (en) * 2003-04-30 2011-05-04 Purdue Pharma L.P. Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20060194826A1 (en) * 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
TW201509943A (en) * 2004-03-30 2015-03-16 Euro Celtique Sa Oxycodone hydrochloride composition, pharmaceutical dosage form, sustained release oral dosage form and pharmaceutically acceptable package having less than 25 PPM 14-hydroxycodeinone
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
SK286087B6 (en) * 2004-08-18 2008-03-05 Zentiva, A. S. Method of preparation of oxycodone
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
WO2006125074A1 (en) * 2005-05-17 2006-11-23 Brown University Research Foundation Drug delivery formulations for targeted delivery
RU2423997C9 (en) * 2005-07-05 2011-11-20 Эббетт ГмбХ унд Ко. КГ Composition and dosage form containing solid or semisolid matrix
FR2901478B1 (en) * 2006-05-24 2015-06-05 Flamel Tech Sa MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE
SA07280459B1 (en) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US20050096388A1 (en) * 1996-05-24 2005-05-05 Angiotech International Ag Compositions and methods for treating or preventing diseases of body passageways
WO2006082099A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant delayed-release forms of administration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BODMEIER R ET AL: "Preparation and characterization of microspheres containing the anti-inflammatory agents, indomethacin, ibuprofen, and ketoprofen", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 2, 1 November 1989 (1989-11-01), pages 167 - 175, XP025484215, ISSN: 0168-3659, [retrieved on 19891101] *
See also references of EP2344136A1

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US8808745B2 (en) 2001-09-21 2014-08-19 Egalet Ltd. Morphine polymer release system
US9707179B2 (en) 2001-09-21 2017-07-18 Egalet Ltd. Opioid polymer release system
US9884029B2 (en) 2003-03-26 2018-02-06 Egalet Ltd. Morphine controlled release system
US9375428B2 (en) 2003-03-26 2016-06-28 Egalet Ltd. Morphine controlled release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8394408B2 (en) 2008-03-11 2013-03-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8668929B2 (en) 2008-03-11 2014-03-11 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US9498446B2 (en) 2009-02-06 2016-11-22 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US10105321B2 (en) 2009-02-06 2018-10-23 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9168228B2 (en) 2009-02-06 2015-10-27 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US9433582B2 (en) 2011-05-17 2016-09-06 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9539328B2 (en) 2011-05-17 2017-01-10 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9468636B2 (en) 2011-05-17 2016-10-18 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9629837B2 (en) 2011-05-17 2017-04-25 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
JP2014525423A (en) * 2011-08-30 2014-09-29 ウニベルシテイト ヘント Multi-layer release formulation
WO2013030267A1 (en) 2011-08-30 2013-03-07 Universiteit Gent Multi-layered release formulation
AU2012327231B2 (en) * 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
JP2015500273A (en) * 2011-12-09 2015-01-05 パーデュー、ファーマ、リミテッド、パートナーシップ Pharmaceutical dosage forms comprising poly (epsilon-caprolactone) and polyethylene oxide
WO2013084059A1 (en) * 2011-12-09 2013-06-13 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly (epsilon- caprolactone) and polyethylene oxide
US20200170954A1 (en) * 2011-12-09 2020-06-04 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
CN104684548A (en) * 2012-07-06 2015-06-03 埃格勒特有限责任公司 Abuse deterrent pharmaceutical compositions for controlled release
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10258616B2 (en) 2013-11-13 2019-04-16 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017103111A1 (en) 2015-12-16 2017-06-22 Universität Basel Abuse deterrent pharmaceutical dosage forms
EP3181124A1 (en) 2015-12-16 2017-06-21 Universität Basel Abuse deterrent pharmaceutical dosage forms

Also Published As

Publication number Publication date
BRPI0913724B8 (en) 2021-05-25
CN102159193A (en) 2011-08-17
CO6361903A2 (en) 2012-01-20
KR20110055734A (en) 2011-05-25
JP2012502968A (en) 2012-02-02
RU2011121010A (en) 2012-11-27
KR101456741B1 (en) 2014-10-31
RU2523896C2 (en) 2014-07-27
MX2011002966A (en) 2011-09-26
ES2586439T3 (en) 2016-10-14
NZ592276A (en) 2012-12-21
ZA201101948B (en) 2011-11-30
US20110165248A1 (en) 2011-07-07
IL211314A0 (en) 2011-04-28
CN102159193B (en) 2015-09-16
AU2009294308B2 (en) 2013-05-30
BRPI0913724A2 (en) 2017-06-20
CA2737257A1 (en) 2010-03-25
EP2344136B1 (en) 2016-06-15
CA2737257C (en) 2016-11-15
IL211314A (en) 2016-03-31
AU2009294308A1 (en) 2010-03-25
MX342643B (en) 2016-10-07
EP2344136A1 (en) 2011-07-20
BRPI0913724B1 (en) 2020-03-10
JP5539991B2 (en) 2014-07-02
NZ601200A (en) 2014-02-28

Similar Documents

Publication Publication Date Title
EP2344136B1 (en) Pharmaceutical dosage forms comprising poly(e-caprolactone)
EP2787978B1 (en) Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
EP2080514B1 (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
JP5704789B2 (en) Alcohol resistant dosage form
AU2013203747B2 (en) Pharmaceutical dosage forms comprising poly(e-caprolactone)
AU2013200246B2 (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
AU2017208264B2 (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
JP2013100306A (en) Alcohol resistance dosage form

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980136742.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09786269

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 211314

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2011527420

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2737257

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12011500547

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 0127011

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/002966

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2121/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: DZP2011000223

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 13105849

Country of ref document: CO

Ref document number: 11045846

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 592276

Country of ref document: NZ

Ref document number: 2009294308

Country of ref document: AU

Ref document number: 2009786269

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117008610

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009294308

Country of ref document: AU

Date of ref document: 20090917

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011121010

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0913724

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110318